outlook
attract industri view hold modestli
greater confid rel perform versu
rather healthcar concern growth
increas exposur value-ori name
catalyst improv
strong start weaker finish multi-year move devic fuel
improv fundament structur drug suppli chain concern show
sign strain sure industri comfort outperform healthcar
point even edg recent contract
rel premium late august current level
seen sinc late period investor prefer shift favor
financi healthcar devic clearli particip within
healthcar clear investor inch back reimburs
regulatory-sensit sub-industri recogn elect risk appear
reflect idiosyncrat biotech catalyst driven signific
appreci last devic under-perform
healthcar point finish may like predictor
start
remain posit group confid devic
out-performance expect pariti vs
confid out-performance vs market given less robust outlook
 per ms macro estim flat ep growth forecast
versu devic coverag see us equiti outlook
rel multipl contract last devic outperform
healthcar point last three year see better outlook
healthcar even elect less convinc devic rel
perform gap vs broader sector intra-healthcar fund flow risk real
overli concern rel fundament remain posit
devic outperform healthcar last six elect cycl
good good enough med-tech industri organ growth doubl
last year breadth improv remain favor
coverag forecast acceler vs last year
model reflect modest improv organ growth vs
setup better last year may enough broad base
multipl expans rate seen sinc suggest
idiosyncrat opportun bottom line pictur suggest earn growth
rel stabl y/i consist materi ahead
macro team expect land ebit margin forecast
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
expand bp vs bp bp less rel
tailwind tax interest buyback primari culprit also
encourag net leverag continu modestli fall
larg cap execut board learn peril transform
 return digest vertically-driven deal see medtron
bd like pursu boston playbook go forward
get challeng fund flow dynam shift acut expect
beyond keep eye china emerg market still drive
larg cap growth price environ soften last
two year pressur provinci product specif nation
initi akin saw drug could alter debat
loom devic tax risk head industri discuss
suggest perman repeal plan base case expect
anoth extens full repeal would taken posit bewar
pursuit growth cost transform deal came went
investor shi away growth like question larger low-return
growth orient case point boston/btg stryker/wright
believ compani take disciplin roic-bas approach
larger deal
narrow growth valu orient growth outperform valu
point year smid beat larg cap point late investor
approach growth valu balanc dust
dcf select stock multipl meaning
elev advers expens secular growth stori
focu what get better across valuat spectrum larg cap that
alcon growth zimmer biomet valu
mid-cap like discount hillrom see disconnect
globu small cap like risk/reward binari reimburs
event irhythm dont believ si-bon multipl reflect like acceler
see signific upsid number axon
upgrad hillrom overweight downgrad baxter equal-weight
theme unifi rate revis valu
 under-own stock healthcar multipl
compress point vs last month
balanc profil see get back defens go look
attract investor conclud legal risk reflect pharma
hillrom top mid cap pick see bedridden long see
meaning multipl expans investor attent shift bed
digit higher-growth pipelin product becom greater portion
revenu mix
thesi baxter take paus see reinvest give paus
account reinvest concern creat overhang
pleas see detail report review theme entir
coverag univers list price target chang found exhibit
summari price target chang
exhibit rate price target chang coverag
valuat methodolog risk associ price target referenc research report pleas contact client support follow us/canada hong kong latin america
 london singapor sydney tokyo altern may contact invest repres morgan stanley research
risk reward remain posit upgrad abbott overweight
 integr risk fade new product launch creat setup core
organ acceler year sinc abbott deliv broad busi
momentum continu compani pace deliv
anoth year organ growth stock work expect
libr mitraclip ncd delay vs expect guidanc came
rais lesser extent opioid fear weigh sentiment
see sever factor revers drive out-performance net debt
ebitda flexibl emerg strateg capit deploy
current valuat perform review
valuat abbott current trade price-to-earnings ebitda
pt base ep reflect ebitda price-to-earnings
multipl larg cap med-tech in-lin high growth peer boston
above-p valuat justifi given better top bottom
line growth rate flexibl balanc sheet
growth look like broad busi momentum seen organ
growth mse continu model organ
growth reflect bp momentum acceler segment level model
growth nutrit stabil china outlook growth diagnost
ngo contract resolut time depend could drive
tailwind bp corpor growth ex-u alin roll-out drive
lab growth growth establish pharma polit disrupt
latam off-set rel stabil china india see growth
cardiovascular neuromod mitraclip set inflect spring ncd see
neuromod return lsd-msd growth closer market libr off-set
tradit bgm declin drive growth diabet see net model
slightli growth see manag guid organ growth
room rais year
mile white departur end era robert ford take helm march
question around transit mean strategi growth
discuss gener expect materi chang commit
growth focu intern innov extern abbott
focus organ growth gener expect transform
strateg action intermedi term given mr white stay execut
chairman compani commit stay cours manag transit
unlik major stock dynam unless strategi shift size increas
growth driver deviat trend
mitraclip libr drive bp growth expect similar
contribut
libr model libr growth contribut pt corpor growth
expect growth acceler come growth year
libr revenu greater penetr global
intensive-diabet popul remain cgm-penetr continu drive
strong double-digit growth libr approv catalyst share
import step drive long-term penetr expect libr
drive distinct inflect cours rather see rel
steadi growth throughout year abbott continu focu access
us pharmaci ex-u vs whose mix weight
similarli see signific risk key
penetr written see room abbott
see strong double-digit cgm growth come year
mitraclip expect ww growth contribut bp corpor
growth see us growth ex-u growth discuss
confid abbott receiv ncd april may support estim
increment improv us mitraclip sale increment bp
abbott growth edward launch pascal europ see
expect launch us
see anoth year dd earn growth abbott averag ep growth
last year includ remain comfort ep
y/i growth vs consensu number driven bp margin
expans account fx headwind bp sale drive
impact earn expect abbott guid ep
abbott remain premium top bottom-lin grower deserv premium multipl
compon upgrad overweight come continu includ
peer lead organ growth continu margin expans peer net leverag
abbott deliv prior quarter outlook sustain
intermedi term bp margin expans low-dd low-teen
ep growth look sustain least next year metric top
quartil among tradit larg cap peer dont expect activ repurchas larg
 could see growth-ori tuck-in exampl structur heart
pt base ep premium large-cap peer group
in-lin high-growth large-cap devic peer
catalyst like drive debat
abbott lab improv invest driven top bottom line
abbott lab improv invest driven top bottom line
price target base multipl
base case ep in-lin high growth larg cap peer
newer product launch libr mitraclip drive expans inflect
quicker expect upsid synergi robust em end market provid
tailwind nutrit stage strong recoveri larg share gain china
new product launch mitraclip inflect sustain organ growth
profil medium term margin grow per year support
libr fail gain traction us confirm mitraclip adopt slower
expect neuromodul growth slow nutrit end market take
longer recov abbott invest grow revenu offset margin
improv em slowdown persist
abbott organ growth sustain
driven broad busi momentum
key product growth libr mitraclip
abbott high exposur emerg
market consumer-direct busi
drive potenti sustain double-
digit earn growth also subject
compani em currenc exposur
highest among devic coverag
leverag opportun visibl across
nutrit diagnost epd peer
margin demonstr potenti
organ growth acceler driven
devic product launch diabet ep
heart failur
continu oper margin expans
core abbott combin cost synergi
execut st jude aler
risk achiev price
emerg market macro slowdown fx
headwind strengthen us dollar
failur libr mitraclip drive top-line
seen sign stabil follow slowdown growth remain
comfort durabl mid- to- low-teen revenu growth profil
go forward catalyst commerci updat encourag
headlin nois well potenti tangibl impact busi follow aha
studi could cloud path forward remain equal-weight lower pt
prior
current valuat perform review
valuat current trade ev sale discount high
growth smid cap peer set like reflect healthi rel lower growth
rate pt base ev sale reflect discount
evid stabil continu manag re-affirmed
guidanc rang earn point investor low end rang
debat outlook control larg unexplain deceler key
franchis pci growth began declin momentum basi volum
bp absolut q/q basi cg slowdown began
q/q volum declin follow sequenti recoveri casual factor
swirl rp disrupt commerci disrupt mix structur cyclic
factor play discuss downgrad note slower growth trend
structur transient especi compani lap seri
catalyst pma reimburs shock protocol etc shift matur phase
market adopt arguabl appar leav us less confid quick
recoveri guidanc impli growth y/i slightli higher
growth still reason especi back impella
roll-out also note comp adjust basi low end guidanc rang
impli pt momentum deceler suggest achiev momentum
well albeit tight absolut dollar basi base histor quarterli revenu
trend manag note octob field rep middl manag hire
complet suggest disrupt commerci infrastructur improv
new hire ramp increment catalyst describ
convinc materi chang revenu growth pictur
invest debat surround impact recent aha data continu
lack clariti drove signific deceler pci cg perform
acut impact lack thereof near-term whether acceler
central focu perform share
analyst day anticip may time-frame like coincid
guidanc new lrp
assess impact aha data studi present aha base
phd data exhibit higher mortal major bleed rate associ
impella iabp see aha note send stock come
aha weekend compani medic offic conduct independ review
larg aim discredit aha studi stress exclus escal
case bias data favor iabp cohort studi simultan publish
circul base info premier healthcar databas patient
show impella use associ greater risk
death bleed stroke aki vs iabp studi base data
around amic patient show higher mortal major bleed associ
impella iabp pci group show even higher rel mortal
bleed rate impella vs iabp gener see circul studi
focu less robust yale studi better match
alarm believ studi impact busi
still assess magnitud importantli view next key debat
catalyst ahead limit releas impella began octob
current site could see expand compani
commenc larger scale roll-out end expect bit contribut
back half continu expect expand sheath come
us like earli year ecp first-in-man still plan around
end march april time-frame although note us
updat time unlik ecp growth driver near intermedi
term japan one meaning catalyst estim point
japan revenu doubl end site count simultan
reach although worth note cp roll-out japan may slow pace
new center add model temper expans end
center count separ full-scal upgrad smartassist platform
like long ramp multi-year process instanc smartassist current
site goal hit
deeper look see gm trend sequenti
compani work add featur pump result manufactur cost
inch ii potenti price haircut iii ex us mix shift price
durabl expect analyst day sourc gm
support compani project across impella cp rp model
drop rang revisit today stood
impress still rang exclud impella sale
trend result solid top line growth see compani continu invest
 see hit high watermark near term continu
expect oper margin surpass
remain equal-weight seen sign stabil follow slowdown
growth remain comfort durabl mid- to- low-teen
revenu growth go forward catalyst commerci updat
encourag headlin nois especi surround aha studi could cloud
infrastructur improv remain equal-weight move pt
equival ev sale repres discount high growth comp
set support dcf
catalyst like drive debat
analyst day like refresh guidanc lrp like may
impella util trend market dynam keep us equal-weight
impella util trend market dynam keep us equal-weight
price target reflect multipl
base case sale high growth devic peer
support dcf valuat assum wacc termin
growth assum sale grow driven continu
impella penetr protect pci shock
impella penetr take faster expect util increas
exist impella site driven new product launch increas data
expans effort organ growth sustain
longer tail stemi repres meaning expans opportun
posit feasibl day multipl expand higher growth durabl longer
dcf analysi equat ev
dcf analysi equat ev
impella growth remain teen medium term repres pt
y/i penetr increas stemi repres meaning expans
opportun posit feasibl data rapidli scale busi surpass
ebit margin multipl high growth peer
lack competit peer profit balanc transit
matur adopt curv
recent growth trend prove anomal impella sale growth deceler
doubl digit multipl contract reflect slower growth profil
potenti market size disappoint and/or expans delay
growth slow seen prior
year teen y/i growth impella adopt
matur busi continu demonstr
oper leverag margin continu
expand bp annual
stemi pivot trial repres key
longer term expans opportun
sustain reimburs broader
pma approv rp launch ecp
broader commerci launch japan
us stemi impli
risk achiev price
risk pt includ usag impact
competit ahead expect market
growth present attract
opportun new entrant pressur
share price iii reimburs risk
annual drg reimburs cut
launch coverag alcon alc spin-off novarti ag april
overweight rate alcon largest medic devic ophthalmolog compani
world revenu expect compani pipelin sale capital-expenditure
reinvest drive inflect top-line revenu growth margin expans
post spin revers share loss iol intraocular lens contact
lens leverag reinvest drive margin stagnat
deploy flexibl balanc sheet despit recent concern
earn dynam see confid upper-ti med-tech return
profil emerg time maintain posit bia
current valuat perform review
valuat alcon current trade ep ep reach
price target use ep multipl discount high-growth
large-cap peer discount back discount back
investor like look toward outer year lrp see
organ growth upper-teen ep growth frame valuat
thesi predic top-line acceler underappreci margin leverag
post-spin commun around increas invest weigh
share recent month see increasingli reflect continu
see top-line acceler beyond driven above-market contact
len growth model contact len growth
acceler iol revenu follow septemb us panoptix
launch model iol growth margin remain back-half
load lrp remain confid upper end rang
continu assum om expans driven pt
gross margin improv pt sg leverag model bp
om expans follow
remain confid upper-ti med-tech return profil emerg time
top-line growth mid-teen ep growth
mix start revenu momentum track expect post-spin
origin model cc growth alcon track cc
growth ytd compani track deliv high end guidanc
model debat shift magnitud
acceler revenu acceler margin factor impact
margin includ fx tariff underli perform consist see
evid pipelin impact margin becom evid
highlight initi see gross margin improv
driven price/mix primarili premium iol panoptix
estim gross margin product effici primarili daili
contact lens although vc manufactur ramp headwind
gm expans discuss
invest year expect see limit gm expans given
surgic mix improv off-set vision manufactur ramp support
model bp y/i expans sens
manag plan continu target spend fuel product
innov intent drive top-line potenti long-term
model midpoint rang spend percentag
sale consist expect sg leverag modest drive
bp om improv om vs prior worth
ep ep headwind establish year see includ higher interest
expens pt increas tax rate associ swiss tax reform
model reflect pt increas net model ep reflect ep
growth ep growth improv high teen
top-line acceler remain like back panoptix recent
manag commentari reinforc convict abil panoptix
inflect sale margin cours continu model
top-line compound-annual-growth-rate line long rang plan lrp guidanc
remain comfort model core oper margin top
end lrp guidanc margin leverag lead high-teen ep growth year
model high end larg cap devic compani price target base
ep estim discount high-growth larg cap med-tech
discount back year wacc alcon busi begin inflect
expect greater appreci compani abil reach high
end lrp target lead out-performance
catalyst like drive debat
progress post-spin cost restructur on-going
product launch drive top-line acceler upper-ti ep growth profil
product launch drive top-line acceler upper-ti ep growth profil
repres base case ep estim slight discount
high-growth larg cap med-tech peer discount back year
new alcon pipelin driver margin initi balanc sheet deploy
drive return materi lrp top-line compound-annual-growth-rate
oper margin alcon reach ep growth
profil lead valuat top end med-tech
spin-off drive valu stand-alon compani alcon abl revers
share loss iol contact lens leverag reinvest drive margin
deploy flexibl balanc sheet lead upper tier med-tech return
profil time margin reach
execut miss panoptix fail catalyz sale growth
margin disappoint compani reinvest drive growth growth fall
lower end lrp rang margin stay low
lead lower valuat
alcon formerli divis novarti
larg cap medic devic compani focus
expect alcon pipelin sale capital-expenditure
reinvest drive inflect top-line
revenu growth margin expans post
spin revers share loss iol
intraocular lens contact lens
leverag reinvest drive margin
see upper teen ep growth profil
emerg time alcon place
upper tier larg cap med-tech
panoptix panoptix primari driver
implant acceler estim
drive bp y/i corpor growth
accret gross margin
primari
driver contact len acceler
estim drive bp y/i corpor
growth
progress product effici initi
risk achiev price
panoptix gain lower
competit particularli contact lens
lower cost on-line provid
margin expans take longer
underweight avano price target avano sold ip busi
sinc face number headwind on-q implement
intern distribut impact growth margin see challeng path
stock estim reset upsid price target driven
better growth margin accret continu see visibl path
upsid compani coverag
current valuat perform review
valuat current trade ep ebitda
estim respect use multipl ebitda reach pt
discount smid peer given avano lower near-term growth profil
busi pressur larg continu next year turn back-half
recoveri avano growth profil remain pressur multipl headwind
chronic histor stabl piec avano busi
distribut issu announc see drive continu headwind
earli model headwind
acut pain on-q suppli concern throughout persist longer
expect although bupivacain ropivacain suppli come back on-line
manag messag around sale recoveri shift past month
avano begun face competit price pressur conced price
drive custom recaptur sens manag expect on-q growth
flat sale lsd growth model low-end
sale addit dynam includ
heron competit consider remain seen
pend approv march pdufa date drive materi shift
neither exparel pacira alreadi avail lal nerv block
evalu beyond hour wherea on-q provid day pain
relief possibl take share exparel shown
clinic impact hour on-q remain standard procedur
requir longer-last pain relief howev on-q lost sale
year exparel first launch avano see similar impact
would view bear-cas scenario avano could see pt hit
corpor growth
coolief reimburs like needle-mov continu expect
coolief growth drive bp corpor growth nearli half
underli growth model consist growth view
appropri given newly-establish reimburs code materi
rais coolief procedur payment support inflect adopt higher
reimburs privat payor cover coolief procedur
today remain goal although would like see chang
net expect underli growth model
contribut addit bp cc growth- half avano cc growth
year specif model bp neom bp summit
immateri contribut endoclear sens manag continu
guid use cc sale growth expect cc sale growth guidanc
year intent reach higher-end model sit
new challeng weaken margin expans outlook model bp gm
expans rel pt previous primarili driven linger impact
distribut issu lesser extent on-going price pressur
acut pain discuss model flat follow bp
improv back half resolut chronic challeng cost save
implement note avano execut post- ip cost transform goal
cost save come within rang plan remain
track reach cost save lower earlier year
target compani june analyst day oper margin
level save drive om expans howev
sens manag bonu payment paid due
busi perform off-set expans bp net come
bp om expans drive om year vs street
year expect avano continu execut cost transform
plan lead om reach high-teen
drive low-teen ep growth addit impact lower margin
expect higher below-the-lin expens weigh ep growth includ
interest expens increas modestli drive ep interest
incom tick given lower cash balanc lower rate drive ep
see avano tax rate share count remain rel flat ultim fall
vs street ep growth improv top-line growth reach
margin expans get back track interest stay rel constant tax
improv slightli model ep growth
strateg action underpin bull case unlik would see
materi acquisit underweight avano sinc late sinc
 ip divestitur may establish avano pure-play devic compani
stock under-perform medic devic pt multipl stay
rel constant ev/ ntm ebitda share near low
acknowledg potenti recoveri revers trade see signific
catalyst drive multipl expans importantli continu see
materi room street margin earn estim come year
ahead said bull case avano includ deploy compani
balanc sheet drive growth accret scenario remain possibl
compani capac believ compani like look larg
 given current implement challeng distribut dynam
top-line headwind expect materi within next month
larger deal several-hundred- mn rang would surpris
compani execut resolv issu mid-year note knowledg
potenti transact
catalyst like drive debat
on-q return growth
restructur execut announc on-going
busi pressur larg continu turn recoveri
busi pressur larg continu turn recoveri
deriv base case scenario price target reflect
ev ebitda multipl discount smid med-tech
market reward avano accret deal near-term recoveri on-q
avano execut larg acquisit drive growth earn accret
growth restructur plan progress accord plan
transform proce estim high avano deliv lsd-msd
organ growth path toward oper margin improv
restructur prove challeng medic devic sale growth low/mid
singl digit restructur initi yield expect benefit lead
lower earn level
transform price
believ investor alreadi price
major benefit post- ip cost
transform risk near-term
revenu headwind make upsid mid-
includ continu headwind within
challeng chronic expect
resolv earli competit
materi upsid requir view
limit visibl time
divestitur ip leav avano
signific capac execut deal
execut deal corpak-lik profil drive
bull case
deploy half deal capac could
drive ebitda accret ep
growth on-q drive pt corpor
on-q return growth
restructur execut
risk achiev price
top-line revenu grow upper singl
signific near-term recoveri on-q pain
avano execut larg accret
overweight axon modul technolog price target
axon receiv fda approv rsnm devic oab fi indic
compani engag high-volum implant axon drive
snm market penetr share gain catalyz market growth see
result key catalyst demonstr earli launch progress
key inflect year follow full us launch
current valuat perform review
valuat axon modul technolog current trade sale
estim price target base estim support
dcf use wacc lower time initi given de-
risk fda approv termin growth rate peak margin
commerci execut focu follow fda approv fi oab
septemb novemb respect focu shift us commerci
execut earn call manag seem support consensu
revenu model sit materi street
revenu predic
share gain assum axon reach us snm market share
base key devic advantag medtron interstim
oab fi-approv snm devic market past year
natur life full bodi mri compat model
next-gen interstim product micro launch impli month
approv time frame follow pma file earli octob
market growth follow recent alphawis survey see model
global snm market compound-annual-growth-rate market growth peak
product innov patient awar effort axon
newli launch websit social media page drive greater therapi adopt
addit comment earlier year impact dementia concern
ach inhibitor could snm therapi survey support
concern drive shift physician treatment toward
get comfort revenu trajectori see revenu ramp
cours put us
year revenu us impli us procedur axon
implant per month doctor doctor perform one
procedur quarter could see us upsid
continu expect launch interstim micro
see compar featur set axon includ size
year life fmri compat recharg constant current deliveri although
earlier launch could drive volatil see competit concern overdon
recent survey indic physician like continu use axon
procedur next year overal market growth acceler
support growth compani comment ip lawsuit
time updat remain uncertain
earn earli could next catalyst sens axon could
pre-announc earn earli januari like week competitor
confer street current model vs model
us see top-line beat drive confid earli commerci traction
recent model chang sens axon manag like remain
focus us growth outsid us ou growth come year
model us ou revenu split year model rel
 previous also updat sg reflect increas spend
associ increment version rsnm devic version
expect compat lead henc avail replac
surgeri version expect primari cell recharge-fre
ramp clinic specialist hire share count reflect recent
remain overweight price discuss initi axon
uniqu opportun disrupt larg market under-penetr patient
popul seen minim innov decad see materi share
gain market acceler support alphawis survey creat
favor invest opportun maintain price target reflect
ev/sal multipl revenu estim discount high-growth smid-cap
peer support dcf valuat number come given
higher out-year revenu slightli lower discount rate reflect de-risk
commerci launch post-approv commerci execut acceler market
growth drive multipl expans
catalyst like drive debat
overweight thesi predic snm share gain market growth
overweight thesi predic snm share gain market growth
price target base sale discount high
growth smid cap peer support dcf
stimul higher growth axon execut expect reach
market share within year competit drive market acceler
benefit compani
take share grow market axon reach market share within
year launch differenti product featur drive share captur
innov acceler snm market growth mid-teen
meet resist axon commerci launch fail ramp expect
competit hit market sooner expect materi lower price
axon market share top teen
axon pois materi disrupt
market histor
domin given superior r-
snm product substanti smaller size
longer life recharg natur
vs current market lead devic
think axon take materi share
ahead competit respons expect
next-gen product compar
superior axon devic
better innov snm acceler
market growth mid-singl digit
mid-teen
clinic specialist hire ramp support
risk achiev price
current physician relationship could
sticki imagin make
difficult gain share
eventu slow share gain
market appetit high-growth pre-
impact multipl regardless
less upsid revenu need reinvest qualiti support capac
may put lrp margin target risk combin account
overhang may take time manag establish momentum investor
note resolut account issu may drive short-term recoveri
share pt prior
current valuat perform review
valuat baxter current trade ebitda estim revis pt
base multipl ebitda repres discount larg cap peer
set primarili given account overhang risk lrp miss compani lower
thesi risk downgrad equal-weight upgrad baxter see
nearli year ago view re-acceler like medic deliveri
stabil signific leverag opportun remain balanc sheet deploy
provid option re-acceler occur may continu margin
reflect see less opportun upsid bigger
shift rel thesi reinvest increas qualiti spend may put
lrp margin target risk expect exist account
investig broaden meaning combin spend dynam see
overhang share although note account resolut could drive
short-term recoveri recent under-perform valuat provid downsid
support number like move lower see prolong path
manag re-establish momentum investor
reinvest necessari accounting-driven restat domin debat
discuss lost shuffl realiti baxter may need reinvest
believ could put lrp risk invest relat
renal support aakhi initi see may understood street
capital-expenditure invest qualiti could surpris downsid challeng
clari opelika infer qualiti remedi alreadi focu baxter two
dynam like factor consensu model
maintain suppli critic baxter taken signific share iv fluid
busi last month concert gpo idn penetr
combin easier compar growth rebound
custom dilig suggest key element captur
extent better price specif contractu assur around
maintain consist suppli agreement place critic
suppli met rais bar requisit infrastructur qualiti
 longer lever investor overlook key sourc leverag
repeat compress bp gener
absolut spend back innov ration
program beyond reduct ill-advis
could impact downstream growth like capital-expenditure invest
associ initi may impair certain extent
see factor put pressur ebit margin well lower
ebit margin assumpt rel lrp
ep estim street
low end lrp
restat like remain line continu believ account
review resolv prior guidanc provid see account
background resolut may drive short term recoveri share
evid issu extend beyond foreign exchang appoint
interim treasur may suggest materi widen scope less like recent
pension transact smaller hedg gain could suppress forward earn
rel prior year previous lower earn see part account
impact downgrad link updat view around issu
acceler thesi aliv well acceler post fluid disrupt key
compon thesi pace acceler may less signific
hope manag provid limit color assumpt stem
model channel dilig analysi suggest baxter deliv
organ growth next year possibl upsid impli initi guidanc
could rel street chang model reflect
lower pharmaceut outlook myxredlin momentum
like off-set supran dexm brevi cyclo albeit moder
headwind expect lower organ growth advanc surgeri mse organ
growth given lower floseal growth stem
reintroduct surgiflow
renal acut like improv driven primarili eas dialysi headwind
like modest impact etc implement prismax roll-out
meaning move renal estim adjust acut acut
margin bp versu prior estim
deliveri subject great debat commentari cfo jay
saccaro around idn gpo see reinvest give paus signal chang
price environ materi one view dilig suggest
flat moder declin price consist prior view estim
combin price harder comp drive deceler line
lrp street
lower revenu estim bp
organ growth midpoint growth would deliv
lrp near lower end reinvest give paus detail review
see outlook segment
downgrad equal-weight see re-acceler anticip
pace fallen short expect underpin previou overweight
thesi importantli leverag gener core tenet
overweight view see visibl cloud pair account
risk lrp may rang bound stock perform near-term lower
price target base ev ebitda multipl
catalyst like drive debat
return growth medic deliveri nutrit
next-gen pump platform launch share captur
re-acceler still possibl pace may slower hope
re-acceler still possibl pace may slower hope
price target reflect multipl base
case ebitda repres discount larg cap peer set
primarili given account overhang risk lrp miss
compani lower wamgr profil assum organ growth
margin slightli expand
baxter margin ramp faster anticip assum compound-annual-growth-rate
back new product initi margin hit higher expect
guidanc om/gm ratio larg cap devic peer
baxter deploy capit wacc return diversifi
baxter achiev organ sale growth new product
geograph expans drive acceler margin continu expand baxter
execut tuck-in medium size deal also buy back stock
baxter new product initi fail deliv growth slow compound-annual-growth-rate
margin expans effort reliant upon benefit product mix fail
materi margin expans slow materi result oper
margin strateg action fail occur deliv wacc
baxter current multipl reflect
wamgr potenti
acceler medic deliveri
nutrit dynam stabil pipelin
baxter premium balanc sheet asset
risk low-return capit deploy
overst expect disciplin
approach involv repurchas
medic deliveri nutrit
headwind stabil contribut
low mid-singl digit growth come
growth leverag opportun
allow baxter reach low-doubl digit
earn growth level includ
acceler
stabil medic deliveri
nutrit drive acceler
baxter expect new product sale
drive pt baxter
deploy balanc sheet
bp margin expans drive
pt earn
return growth medic deliveri
nutrit
next-gen pump platform launch share
risk achiev price
medic deliveri nutrit
recov expect
potenti activ below- wacc
inabl gener oper leverag
baxter struggl grow wamgr
view bd guidanc prudent achiev expect revenu well
margin expans back half heavi move final year bd
bard deal model look sustain top line growth
potenti double-digit ep growth beyond rais price target
remain support growth profil margin expans
opportun guidanc
current valuat perform review
valuat bd trade ev ebitda estim half turn
larg cap devic peer set pt base ebitda line
conserv start discuss note conserv guid
reflect prudent start believ top line guidanc
achiev expect top line headwind across segment see
expect see ramp recoveri throughout balanc year bd
number back half load past two year sens
could bit deja vu although revenu improv like kick earli
versu worth note also er conserv side
number forecast high end potenti alari impact top
china price pressur expect compani full year growth fuel
bd medic bd life scienc bd intervent note
assum type patch estim assum one quarter btk
contribut see
revenu build explain bd medic busi pace deliv
growth md segment track flat primarili attribut
ou given price cut china consum pull china growth low double-digit
high single-digit net headwind repres bp hit corpor
revenu follow growth recoveri mid single-digit level
compani look off-set china price nois elsewher ou expect see
us declin result alari upgrad lead temporari scale-
back shipment bp headwind corpor revenu
expect backfil rest year
pronounc rebound despit new competit baxter manag confid
bp pump share gain well continu strength pyxi
grow double-digit europ previous discuss expect diabet
flat resum growth start growth busi slow
given price pressur notabl expect revenu contribut type
patch await regulatori updat expect pharma system
remain sustain busi deliv mid single-digit growth bd life scienc
expect preanalyt bioscienc track mid single-digit
growth propel catalyst capac invest ultratouch push
button pa facsymphoni facsduet adopt expect diagnost
growth volatil intra-year given tougher comp
still deliv solid growth sbd intervent expect deliv
growth surgeri expect deceler slightli given tougher comp progel-driven
still deliv growth primarili driven european biosurgeri dcb
headwind eas impact anniversari mid drive growth overal
expect pi busi grow versu compani
bake btk contribut guidanc estim btk could contribut
one quarter revenu base pma submiss base
case approv timelin thereaft continu expect urolog solid
steadi grower deliv mid single-digit growth purewick continu
ep acceler fuel growth capit develop broadli expect
margin expans back half load given dcb anniversari mid-year drive
gm improv ii revenu acceler back half financi
stori look dissect ep movement piec fx headwind
hit ep om expans materi ep headwind moder interest
expens tailwind gore royalti rolling-off headwind slight
tax rate movement contribut headwind upsid ep could come
increment margin expans compani refinanc cheaper debt
addit bp om expans could tailwind ep bp
interest save support ep expans bard synergi also expect
fulli wrap overal expect ep acceler grow
dynam bd expect hit target leverag
posit begin dedic excess cash share repurchas tuck-in
 said compani like execut buyback end
aggreg spend like becom aggress
maintain equal-weight bd move final year bard deal model
look sustain top line growth potenti double-digit earn
growth roll-forward valuat analysi rais pt base
catalyst like drive debat
updat lutonix dcb updat btk
revenu synergi cross sell bd bard product move final
year deal model
realiz anticip cost synergi tax opportun on-going
growth return intact final year deal model
growth return intact final year deal model
price target base multipl
base case ebitda line larg cap peer set
better pipelin execut drive organ sale acceler bard drive
addit growth high singl digit bd deliv synergi materi
forecast ahead schedul manufactur reloc erp
implement yield greater expect benefit drive oper margin
organ growth sustain becom evid new product
ramp cost program gain traction bard synergi integr
bard integr take longer anticip organ growth slow due
addit eu auster poor pipelin execut dwindl us cash
reserv push buyback poor execut cost initi addit
price pressur limit margin expans see bd multipl contract low
end devic peer group
sustain growth profil
potenti double-digit earn growth
head last year deal
model bard remain meaning driver
margin improv lever growth
acceler support em penetr
aggress action cost may
em repres around sale
may drive much third revenu
growth acceler profit doubl
digit growth like requir bd
comfort achiev exceed guidanc
bd estim cost synergi
like floor ceil bard
drive meaning growth acceler
beyond
updat lutonix dcb on-going updat
btk
realiz anticip cost synergi
tax opportun on-going
risk achiev price
integr fall behind schedul
promis synergi fail materi
macro trend get wors competit
pressur em mount
new product launch fail live
convict boston continu rest tripl threat thesi top line
growth continu acceler compani track deliv growth
outlook point path growth solid
underli organ growth boston expect close year deploy
up-front capit advanc diversifi matur pipelin path
out-performance rest acceler top line growth profil boston
integr deal organ pipelin continu matur margin
expans drive mid-teen ep growth clear path forward non-
core btg pharma/licens divestitur rais pt
current valuat perform review
valuat current trade ntm ep broader larg cap
med-tech price target base ep larg cap
med-tech line high growth peer abbott
given boston outlook high singl digit organ sale mid-teen ep growth
magnitud boston acceler triple-threat thesi
continu underpin multipl path acceler coupl track record
acceler track compon
bp corpor growth exalt bp
structur heart set deliv outstand growth across multipl
heart aggreg drove boston growth
respect project drive compani growth
medsurg also pois deliv low double-digit growth given exalt-d launch
well continu strong urolog organ growth bolster inorgan
contribut rezum
boston expect close deploy total capit
advanc diversifi pipelin expect put boston path
total revenu growth particular expect btg deliv total
revenu drive inorgan corpor growth vertiflex
deliv total revenu augmenix contribut
recogn risk growth name achiev lotu on-
track perform mse pacer expect slight declin
low single-digit de busi declin mid single-digit due price
pressur although repres improv
beyond growth driver boston posit doubl
growth organ pipelin unfold integr
cardiovascular continu trend expect de headwind continu
low- to- mid-teen declin us declin ou driven
primarili price pressur lesser extent ischemia nois
laid post-aha note see ischemia result present last month
could slight headwind util could translat
headwind bp total boston growth structur heart front
quit tailwind push busi watchman
continu carri major busi expect sh
busi propel catalyst flx mid back half
japan roll-out believ structur heart close ramp
segment level alloc across watchman pt lotu pt sentinel
pt acur pt within pi ex btg call eluvia
meaning driver potenti ad revenu contribut pt
segment growth bp corpor growth continu expect
launch ranger although believ materi growth driver
expect rel flat y/i icd deliv low single-digit
growth pacer continu low single-digit declin global
expand presenc dual chamber pace market introduct
micra av spring could creat competit pressur boston dual
chamber pace balanc like meaning futur
year see micra av assumpt ep expect grow high teen
underli growth core franchis deliv double-digit growth
addit growth contribut cryo rf singl shot
medsurg pace low double-digit organ growth inorgan upsid
primarili come exalt-d launch expect drive
revenu lot headroom growth manag
believ itll achiev run-rat peak-sal basi conserv base
case point opportun recent acquisit track
turn organ howev still expect deliv strong growth
augmenix rezum y/i
expect boston initi process divest zytiga licens royalti
acquir btg leav btg pharma revenu base
boston complex continu expect divestitur piec btg
pharma busi project single-digit declin go forward
remain btg peripher revenu base expect deliv double-
digit growth upcom sunset pe complet leav us encourag
growth trajectori notabl us piec like come pressur
ex us portion expand cross-sel certain ou geographi
btg revenu mix nearli us ex-zytiga possibl btg ex us mix grow
line broader boston pi
convict mid-teen ep growth feel good achiev pt
om expans although note manag like guid
bp expans given anticip reinvest stem lotu exalt
spend addit believ compani err conserv side guid
 top line growth expect ep guidanc note sever
headwind tailwind ep growth throughout model
interest increas ep decreas expens ep
tax rate rise ep pt om expans ep
reiter overweight favor view boston continu rest solid
triple-threat thesi underpin overweight rate maintain pt
base ep multipl repres premium larg cap peer set
ep given boston attract growth margin expans prospect
leverag profil line high growth peer abbott
catalyst like drive debat
augmenix roll organ close non-cor btg segment divestitur
peer top bottom line growth drive posit risk-reward
peer top bottom line growth drive posit risk-reward
price target base multipl
base case ep assum trade larg cap peer
justifi superior emerg growth margin expans
opportun leverag profil line high growth
peer
fire cylind organ growth acceler doubl digit
pipelin program outperform sale inflect faster expect high
increment profit new growth driver better leverag recent
 acceler margin expans drive high teen greater ep growth
sustain execut support acceler high singl digit large-cap growth
stori recent build pipelin program drive sale compound-annual-growth-rate
oper margin remain track bp annual
improv next sever year drive mid-teen ep growth
base case reflect multipl ep estim larg cap
devic given boston attract growth margin expans leverag
profil line high growth peer like
pressur multipl front acquisit prove less accret organ growth
key pipelin product fail come market tavr fail gain traction
stent price share pressur increas weigh organ
matur pipelin augment
drive sustain hsd organ growth
profil bp annual margin
expans drive mid teen ep growth
support premium valuat peer
revenu growth better
sustain boston shift
faster end market share gain
continu wamgr shift today
margin expans driven
integr oper effici balanc
sheet flexibl improv
boston move past mesh ir litig
pipelin focus expand
higher growth end market wamgr move
long term margin expans target
beyond suggest plenti room
continu margin expans
balanc sheet deploy seen
rapid pace
roll organ close non-cor btg
risk achiev price
achiev lotu expans
increas competit core de
market competit product
failur execut plan pipelin
program integr
follow growth year question longer whether
lrp call compound-annual-growth-rate conservative- magnitud
beat acknowledg libr present new advantag
icgm bluetooth transmiss alert alarm lower price point vs
us intensive-insulin popul still cgm penetr
global penetr remain see compani success
year beyond remain comfort model
revenu rel lrp howev current valuat street
like factor much optim leav us equal-weight
current valuat perform review
valuat current trade ev sale price target
base ev sale line high growth peer support dcf
analysi wacc termin growth rate
bridg first month less-catalyst rich ahead
libr concern remain focu given like launch said
highlight non-catalyst year follow launch
face libr origin anticip yet factor flip tailwind
traction pharmaci drove inflect us volum intern
penetr driven ex us growth libr approv remain
outstand expans stori support lower barrier access
patient pharmaci distribut prove enough drive
robust volum growth off-set annual price headwind even
absenc new product launch expect strength continu ahead
late remain comfort sale estim
y/i growth pt ahead street like provid growth
guidanc midpoint perhap rang
model us revenu vs consensu reflect pt
momentum deceler model ex-u revenu in-lin
consensu reflect pt momentum deceler math dexcom
us patient global
model materi impact expect launch
ramp smaller size longer life day attract
form factor hardwar expect support inflect volum
greater penetr pharmaci becom attract
treatment option intens perhap take and/or ex-u share
abbott
japan launch import long-term growth driver sens
see materi contribut japan late
earli roll-out scale meaning
despit lrp conservat see expect manag host
anoth analyst day updat lrp ahead launch late
sens could see decemb analyst day updat long-
price vs volum key debat cours manag grown
increasingli transpar around long-term price strategi goal reach
premium libr rel estim price premium today
compani expect see increment increment price headwind
consist driven conced price expand access
pharmaci launch medicar hardwar revenu stream declin
importantli volum off-set price headwind use us
revenu less major price headwind impli
us patient like ex-u patient estim
whether volum off-set anoth year headwind remain question
confid on-going traction model pend price headwind
realiz reflect patient count reach us patient
see anoth year signific margin expans support increas profit
expect expand manufactur continu scale partial
off-set new manufactur pressur sens
follow similar progress saw launch
model follow oper expens
leverag like continu model bp expans
ratio revenu growth opex growth improv
expect trend continu model revenu growth opex growth
impli increas y/i opex vs net arriv
ep vs street
lrp decidedli conserv question conserv follow
growth year question longer whether lrp
call compound-annual-growth-rate conserv magnitud
beat acknowledg libr present new advantag bluetooth transmiss
alert alarm lower price point vs us intensive-insulin
popul still cgm penetr global penetr remain
see compani success year beyond
remain comfort model revenu rel
lrp howev current valuat ev sale premium vs high-
growth peer street like factor much optim leav us equal-
weight price target base ev sale support
dcf valuat key assumpt includ wacc termin growth
catalyst like drive debat
expans vs competit price risk impli polar risk-reward skew
expans vs competit price risk impli polar risk-reward skew
price target reflect ev sale
multipl in-lin high growth devic peer
expans drive continu inflect penetr rate guardian
libr traction limit prove market expans premium price
sustain libr seen inferior product success non-
intens popul pbm distribut drive clear path om
revenu growth sustain expans outweigh
competit pressur price pressur larg off-set volum
shift pharmaci integr system launch drive ww growth
juri remain type adopt rate
lower share price pressur limit profit guardian libr
becom competit core medicar user libr disrupt price
model sensor price collaps cgm fail gain traction non-intens
popul delay unabl drive gm expans
continu glucos monitor cgm
secular growth stori ampl room
expans see long runway cgm
penetr grow long
term driven product evolut
elimin fingerstick test improv
form factor integr insulin deliveri
dtc drive near term us
technolog leadership
sustain late
competit present risk especi
relat price
volum driven shift pharmaci
distribut off-set price
new patient larg
europ penetr sustain strong dd
advantag new competitor
shift pharmaci distribut on-going
risk achiev price
guardian libr competit
greater expect limit new patient
start materi increas attrit
limit path profit
delay failur pipelin catalyst
upsid look increasingli like tavr growth slow risk
tavr skew posit earli tavr pascal bridg
mitral replac tricuspid pipelin matur remain overweight
maintain pt
current valuat perform review
valuat edward lifesci current trade ntm ep price target
equival ep support dcf analysi assum
wacc termin growth
come analyst day earlier month tavr guidanc modestli better
bottom end assum less share compress market model
project bp share loss like assum pressur boston lotu
low-risk captur model project high double-digit high
single-digit y/i growth vs reflect momentum stabil upsid
factor bp share compress worth pt tavr growth
momentum consist tavr growth would closer vs
expect trend may play role increment stronger
pipelin perspect manag announc sapien focu
optim safeti efficaci first-in-human complet pivot enrol
less month away timelin reflect increas regulatori hurdl
europ mdr need lock design perhap conservat given
recent issu associ ultra deliveri system statist better
perform unlik numer improv like paravalvular
leak pvl pace preserv coronari access
bigger consensu appreci rate low-risk penetr
ultim symptomat sever aortic stenosi sa tavr market size key structur
question manag reiter tavr market estim
increment posit skew prematur evalu earli tavr
asymptomat sever aortic stenosi given emerg data set like recoveri
aha popul increasingli come view manag introduc
concept moder risk see insid detail meet asymptomat
market could equival symptomat neither popul reflect
intermedi term model patient recoveri younger bicuspid sever
treat mechan valv earli tavr patient older mainli tricuspid
avers surgeri larg trial patient given
endpoint data less like
separ studi center around potenti poor surviv rate patient
base moder aortic stenosi neda registri see indic
patient patient moder sever
respect within studi popul studi conclud moder
patient risk similar sever patient exhibit
poor long-term surviv patient moder aortic stenosi jacc
tmtt guidanc consist top end lower bottom end still
call doubl revenu low end reflect impact pascal sheath issu
could drive flattish trend updat tmtt revenu
tmtt number pascal go
lion share tmtt next year despit enrol cardioband
next major inflect pascal us approv like case last
year tavr potenti legal headwind pascal includ
guidanc trial begin month uk us may germani juli
outlook major program chang analyst day note
respect trial pipelin versu expect line view cardioband
remain labor requir second gener devic drive broader use timelin
disclos expect second impair charg taken mitral
develop unlik tavr linear debat shift tavr
develop mitral tricuspid program go critic stock
surgic structur heart critic surgic outlook bp lower
midpoint last year guidanc outlook reflect greater develop
market tavr eros off-set mix shift higher asp inspiri growth
emerg market growth well late sutrafix launch harpoon remain
track small separ investor less focus critic
import note segment improv last year driven
pt corpor top line growth assum outlook would slow guidanc
versu model reflect continu growth contribut hemospher
well clearsight foresight contribut
low-risk remain driver still expect lever earn summari overal
revenu line expect vast major tmtt slowdown off-set
stronger critic outlook exhibit guidanc vs expect guidanc
deceler dynam vs unsurpris model
margin gross margin expans limit given well telegraph fx
headwind devic tax includ guidanc manag
suggest could off-set portion potenti impact
impli margin flexibl sg leverag expect flat
midpoint line expect may signal high water mark
edward opportun futur leverag
non-op item share count inch higher impli less activ buyback tax
rate better expect higher stock compens
net model ep growth ep upsid tie tavr perform
bp tavr upsid bp margin upsid ep
catalyst like drive debat
tavr market expans continu low risk mitral catalyst
tavr market expans continu low risk mitral catalyst
tavr market reach global see gradual
expans low risk popul follow low-risk data
complement growth rate higher risk us eu popul
ew share declin time remain market leader
coapt result mitral path forward key edward trial
timelin launch need addit clariti oper leverag
acceler long-term margin reach
edward maintain share market share tavr market grow
bn tavr increasingli becom therapi choic even
low risk patient drive penetr global mitral innov
progress faster expect price declin lower expect
base case ep support dcf base analysi
base case ep support dcf base analysi
tavr market reach global see gradual expans
low risk popul follow low-risk data complement
growth rate higher risk us eu popul ew share declin
time remain market leader coapt result mitral path
forward key edward trial timelin launch need addit clariti
oper leverag acceler long-term margin reach
risk prove bridg far valv durabl remain outstand issu
younger patient still tavr market grow billion
limit low risk intermedi risk traction sapien share slip
traction acceler competit boston off-set
peer
long-term potenti market expans
lower risk patient remain
underappreci drive
out-performance time see market
expans billion said
near term intermedi risk penetr
durabl reflect growth inflect
continu see increment
ebitda margin tavr sale
drive long-term corpor ebit margin
high near term reinvest like
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reflect signific uncertainti
futur market
penetr tavr lower risk
popul critic near term
increas visibl structur heart
portfolio key durabl long term growth
risk achiev price
robust commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
mitral space
us european reimburs pressur
price time
equal-weight envista current price target
follow second step separ announc novemb
set envista clean execut key investor expect
acceler top-line flat lsd mainli driven spark expect
traction drive upsid margin estim like conserv see mix
cost program drive upsid like key driver valu near-term
valuat reflect futur acceler still unproven leav us equal-
current valuat perform review
valuat envista current trade ebitda estim turn
discount vs core peer see ebitda
discount dentspli appropri given lower growth margin profil slightli
off-set superior yield vs envista acceler top-line
expand margin faster anticip like drive expans multipl
tighter discount end-market volatil mute uptak new product would drive
stagnant multipl
new product drive top-line acceler key compon envista invest
thesi surround top-line acceler follow three year flat growth model
impli organ growth growth ex disc item acceler
segment driver tale two citi discuss sp
model growth vs primarili driven spark
lesser extent product driver ration
initi valu implant anniversari creat softer comp
theme focus end-market stabil model flat growth
price continu risk impact trend
recent howev new product introduct ration effort
stabil price see guidanc organ like see potenti upsid
driven spark traction
spark drive sp growth model growth momentum acceler
throughout year sp spark contribut build launch eu
us thereaft spark manag commentari suggest
product drive forecast growth acceler impli
increment sale bp note modestli
estim increment sale bp growth consist
thesi spark materi growth driver current model impli
market share spark howev increment bp drive
bp growth contribut mostli deriv europ
expect mid-year launch contribut fda approv expect thereaft
howev see back-half scenario limit contribut
us next year model sale drive bp growth net
model impli spark drive organ growth estim see
initi detail revenu build
 stabil focu weaker equip trend demand primarili
europ weigh recent result expect persist see flag
channel dynam particularli key risk thesi see basic
equip demand remain weaker temper growth howev
compani launch two intra-or scanner previous presenc
market help stabil growth see model includ
modest contribut scanner bp may prove
conserv industri commentari suggest tradit consum market
stabil lsd growth still experienc price pressur expect
consum grow flat lsd net model flat segment growth
see possibl driven new product launch channel stabil
would drive increment bp corpor
margin like conserv margin bp estim
improv bp q/q driven earli traction cost program well sale mix
ampl room margin improv driven favor mix cost reduct
initi key part thesi alreadi shown traction modestli rais
margin estim bp y/i vs flat prior base
follow factor sp growth acceler drive favor mix
contribut bp alon weaker equip demand also expect
persist drive favor mix higher margin segment major
cost save program expect drop see traction build
cost save drop would impli bp
margin upsid headwind see price increment public compani cost
bp impact margin net see bp y/i margin expans
achiev drive ep expect ep guidanc bracket
street like prove conserv given expect margin upsid model
ep y/i growth remain comfort consensu
set clean execut remain key follow split-off announc
remov key overhang see focu shift envista abil
acceler top-line via new product launch drive margin although
commentari recent posit spark contribut next year execut
remain key remain equal-weight valuat ebitda vs dentspli
alreadi begun reflect futur acceler howev given superior yield
vs dentspli posit inclin view could becom increment
posit traction lead faster top-line acceler lead
addit upsid neg risk includ price pressur end-market
volatil updat price target base ebitda turn
discount dentspli given lower top-line growth acceler yet proven
catalyst like drive debat
spark clear align launch us on-going
price target base base case ebitda
estim discount see justifi
given lower growth margin profil howev modestli off-set
envista maintain superior yield vs dentspli
spark uptak occur faster anticip growth acceler
onward result favor mix combin
cost initi drive bp margin annual impli mid-teen earn
growth forese futur price pressur less sever statu quo
envista anniversari channel disrupt segment
ration effort pressur implant growth segment return
market growth spark acceler growth
distributor realign ensu volatil channel new product uptak
mute competit pressur rise dso preval drive
materi price headwind pt per year growth remain
rang margin expans limit due price unfavor mix
envista lead manufactur dental
implant comprehens portfolio
equip consum
compani move past acut industri
disrupt past year
launch sever new product
drive revenu acceler
margin expans initi could
meaning driven improv product mix
cost save program
pt market share clear
align market drive pt organ growth
pt market share fully-tap
implant market drive bp organ
bp margin expans drive pt
reduct interest expens
share repurchas bp reduct tax
rate add pt ep growth
spark clear align launch us
risk achiev price
price pressur result dso
mute new product uptak implant
spark clear align
distributor realign result
equal-weight globu medic current price target vs prior
multipl avenu growth driven recent expans trauma recon
imag set globu potenti year top-line acceler convers
expect invest remain elev manag allud modest margin
expans drive leverag expect ep growth near mirror top-line
growth invest case look brighter see valuat
adequ reflect leav us equal-weight
current valuat perform review
valuat globu current trade ebitda estim turn
smid cap devic peer valu globu ebitda modestli
smid cap devic peer see warrant given outsiz organ growth profil
slightli off-set limit upsid current valuat limit multipl expans
organ growth maintain dd sustain modest contribut
 leverag see bull case ebitda reason
spine strength continu estim globu pace us spine growth
would mark strongest perform year driven
competit rep hire excelsiu pull-through new product
expect hire remain strong pull-through acceler robot instal base
continu ramp model us spine growth may prove
conserv see reason expect deceler increment point us
spine growth drive bp corpor sinc organ growth
materi acceler flat mid-teen compani re-organ
sale forc undertaken target go deep approach oppos wide
commentari suggest mid-teen growth appear sustain howev given
challeng comp comfort model growth increment
point growth drive bp corpor expect globu
guid revenu vs consensu consist prior year
expect modest rais throughout year globu deliv
top-line upsid vs initi guidanc track upsid model
revenu organ remain comfort
robot remain competit imag could drive upsid enabl
competit concern becam key part invest debat
robot placement materi consensu driven multipl factor
includ competit dynam longer sell cycl see market
remain competit aggress bundl strategi like
meaning chang howev potenti spine
robot expect next sever year sell cycl could lengthen late
robot expect model flat robot placement y/i
expect quarterli volatil impact share price perform note
increment placement drive bp corpor growth globu showcas
imag platform nass expect launch mid-year see revenu
contribut depend time approval/launch commentari
optimist date asp system could worth bp
corpor growth net enabl growth stabl acceler
imag factor model model segment growth drive
bp corpor
trauma contribut impact although revenu
disclos expect trauma revenu larger year
trauma sale forc built full bag product anoth
wave hire could come depend speed ramp manag
previous allud consensu model trauma revenu
manag express comfort commentari suggest compani may
disclos revenu later year given small base full bag product
globu scale see like conserv impli share
ww trauma market spine ramp closer bp per year admittedli
much earlier ramp given exist resourc scale expect upsid
trauma number model trauma revenu drive bp
corpor increment bp share captur drive bp organ
recon strategi consist commentari time acquisit absent
invest core recon growth like mute real driver stelkast
acquisit robot offer expect aao
question becom globu compet unsurprisingli littl
disclos compani allud prior strategi spine robot
develop market superior offer see difficult given mako
rosa what import expans opportun
still exist meaning runway recon robot like system uniqu
element expect offer akin rosa mako perhap lack
integr saw haptic origin discuss differenti could come
mani form includ target revis use price focus specif site
servic ie howev manag convers recent suggest
price robot and/or implant target strategi soon
call whether get addit detail system aao
see aao like
anoth invest year ahead greater earn leverag expect invest
trauma robot pressur margin toward lower end
adj ebitda rang model expect invest remain elev
target trauma imag recon robot develop said
manag commentari point expect modest margin expans
invest less meaning top-line growth continu
drive leverag model bp margin expans bp adj ebitda margin
expans drive bp earn howev similar last year note consensu
expect bp oper margin expans ep aggress
like come throughout year model ep y/i
expect ep growth close mirror revenu growth notabl revers
invest case look brighter valuat leav us equal-weight bottom-
build potenti top-line acceler look compel globu
multipl driver upsid model organ growth see dd
achiev mute leverag key compon equal-weight thesi
head see larg play discuss
expect greater leverag ep growth line top-line growth
potenti acceler top bottom line leav invest case
look compel howev valuat ebitda vs smid cap peer
see larg reflect remain equal-weight note
current turn valuat disconnect vs ntm ebitda point
higher averag sinc price target base ebitda
modestli smid cap devic peer bull case see trauma ramp faster
intern grow high teen increment robot
placement scenario valu globu ebitda bull case
valuat given dd organ growth profil
catalyst like drive debat
addit indic applic excelsiu
shift end-market growth spine on-going
potenti use balanc sheet on-going
deriv base case scenario price target base
ebitda modestli smid cap devic peer see
off-set limit leverag opportun
globu continu acceler top-line via expans opportun
robot trauma recon robot placement acceler y/i
technolog gap vs mazor widen competit longer-d trauma
ramp faster anticip becom meaning driver growth
intern sustain grow mid-to-high teen organ growth
profil shift becom dd sustain drive greater leverag
core spine busi continu grow comfort market driven
innov robot pull-through robot market remain competit
globu continu modestli increas system placement y/i heighten
invest limit leverag ep growth howev globu abl
deliv modest margin expans drive hsd ep growth
end-market challeng spine combin competit pressur
robot globu core spine busi grow low-singl digit market get
challeng price pressur increas competit challeng
robot persist greater extent excelsiusgp placement declin y/i
trauma contribut remain limit invest continu weigh
globu demonstr abil
maintain innov lead core spine
diversifi lead multipl
avenu growth includ core spine
robot trauma recon
robot placement continu drive
sentiment see ampl runway
multipl system market
 leverag mute given
heighten invest howev expect
modestli revers lead
attract invest case
bp organ growth
trauma bp market penetr
impli bp organ growth
bp growth
point organ growth upsid drive
bp ep
addit indic applic
shift end-market growth spine
potenti use balanc sheet on-going
risk achiev price
competit dynam robot intensifi
end-market pressur spine
heighten invest continu
market plasma growth profit inflect led point
out-performance vs mid-august howev modest deceler
plasma collect volum lack larg custom contract announc
driven recent share pressur continu model larg custom contract come
expect becom key investor focu come quarter absent
contract analysi impli oper excel program
off-set foregon ebit benefit custom contract remain
overweight share pt continu see materi
profit inflect come year
current valuat perform review
valuat haemonet trade ebitda estim turn higher
smid cap comp group see justifi given organ growth
profil shift hsd ldd ep growth exceed compar
smid cap grow msd organ grow ep valu haemonet
ebitda estim premium smid cap peer base superior
organ ep growth profil
plasma collect volum rebound plasma collect volum growth msd
well seen true underli caus yet uncov
could attribut declin number donor improv economi
ineffici center and/or anniversari tough comp econom factor
challeng comp like ineffici view
monitor dont see caus alarm given collect center
feedback call rebound histor rate fluctuat
ppta notifi fda igg shortag back august
see demand trend continu model organ growth
plasma bp growth remain comfort howev debat
clearli shift growth absenc larg custom contract announc
discuss
expect focu shift larg custom contract come month model
addit larg custom contract grifol come drive pt
increment plasma growth recent convers suggest custom
still run pilot program adopt nexsi system full yet
feedback also impli may cost sensit elong trial
period indic neither rush make decis remain comfort
embed contract estim lack clariti regard time may pose
risk come quarter expect primari invest debat
haemonet next sever month note revenu expect
drive increment ebit price benefit modestli off-set depreci
drive point margin
blood hospit segment tale two citi hospit growth guidanc
organ reiter follow point momentum acceler driven
teg impli point momentum acceler
driven addit sale rep new product launch model
midpoint guidanc remain comfort blood continu model
growth declin amplifi given custom loss model
note annual creat softer comp
model segment growth point corpor consist manag
commentari suggest segment maintain lsd/msd declin adjust
restat declin would still reach high end segment lrp
see potenti strateg activ come debat come year
segment stabil believ compani activ engag process
see margin guidanc conserv margin guidanc impli
bp lower note break histor trend margin averag
bp higher past year manag allud sale forc
expans plan hospit segment still see margin guidanc conserv
discret spend highlight margin flat
would impli ep upsid past three year
full-year ep come current guidanc impli midpoint
assum ep deriv would impli point
ep upsid buy-back activ drive upsid current
incorpor model remaind buy-back activ
share drive increment upsid model margin
ep like prove conserv
oep program repres upsid factor consensu estim
compani recent announc oper excel program oep set provid
cost save commentari suggest major
drop begin realiz save see program drive
bp margin current factor model
consensu estim coincident npv cost save program roughli
equat lack ebit upsid larg custom contract subsequ nexsi
price benefit key debat move forward rest whether cost
program either off-set supplement benefit larg plasma contract
analysi impli absent contract model drive
increment ebit cost program like provid drop save greater
suggest npv cost program off-set lack
profit drive thesi focu shift contract mid-august
haemonet share climb vs driven robust plasma growth
nexsi price continu tailwind materi profit inflect howev
share trail concern regard plasma collect volum larg
custom contract came debat discuss expect larg
custom contract key investor focu near-term regardless analysi
impli profit inflect continu without contract see
compani becom activ capit deploy buyback
potenti long-term explor strateg option blood busi remain
overweight share price target base
ebitda estim turn premium smid cap peer given superior organ
growth profil materi greater oper leverag
catalyst like drive debat
announc larg custom nexsi contract tbd
capit deploy via buyback on-going
progress cost restructur program on-going
price target reflect ebitda five-turn
premium smid cap peer given superior organ growth profil
upsid nexsi price complex reduct initi drop
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi cost restructur program drive ebit
haemonet abl achiev favor increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl creat
materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
stori tie long-
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi compani
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
drive materi inflect
nexsi drive increment valu
per liter plasma custom
haemonet expect particip
oper excel program
drive bp margin
capit deploy via buyback
announc larg custom nexsi
capit deploy via buyback
progress cost restructur program
risk achiev price
larg custom declin convert
save program fail materi
valuat discount wide upgrad overweight bia hillrom
inch higher recent quarter pipelin connect care contribut drove
pt pt organ growth acceler improv went
unrequit hillrom lag peer pt linger confus growth
reconcili fear compani still reliant bed centrella see
acceler momentum given shift digital/
connect care pipelin product drive balanc growth across segment
emerg market invest recognit durabl organ growth
profil narrow turn discount peer rais pt
current valuat perform review
valuat hillrom current trade ep ebitda
repres discount versu median smid peer ebitda
price target reflect ev/ebitda multipl estim
discount smid peer
old new investor focus hillrom tradit
busi fail appreci three invest area transform organ
growth fact growth improv investor
question sustain centrella signific driver grow
contribut point growth versu expect bp
see lsd-msd centrella growth guidanc prudent perhap conserv
focu upgrad new invest driver real quantifi
poorli understood street
digit connect busi includ voalt
see grow drive bp corpor growth
year digit go hillrom year
pipelin drove pt growth see product base continu
drive pt growth relat add-on new product
launch drive pt growth annual
emerg market repres revenu today see em grow
faster given ceo john groetelaar recent initi
replac manag refocu growth em growth drive bp
bp growth model
told driver contribut pt organ growth assum
remain hillrom grow low-end compani wamgr visibl
growth much better consensu multipl assum expect growth
shift becom appar across balanc drive multipl expans
margin offer upsid flexibl invest hillrom demonstr consist
abil drive margin expans averag bp per annum last five year
bp ebit expans reach guidanc look conserv vs
mse bp continu see opportun hillrom deliv bp per
year upsid reinvest growth recent issu lrp lay
om impli bp annual om expans sens
digit recent vision product launch spotvis retinavu respiratori
portfolio monarch breath math collect
becom revenu could impli gm guidanc conserv
model in-lin lrp guidanc gm level bp ahead om
drive compound-annual-growth-rate street-high earn
lrp
portfolio manag move wamgr hillrom wamgr recent
action divest declin segment acquir higher growth risk-adjust recip
success creat valu peer includ boston
scientif whose wamgr start low singl digit deal prior manag
mix follow differ script recent surgic consum
divestitur busi declin lsd annual breath voalt
acquisit expect contribut grow strong
double-digit asset swap like pt accret organ growth
hillrom capac deploy net debt ebitda expect
tuck-in rang next
includ lrp see lrp thought digital/ care commun
manag greatest area interest invest multipl
could wrong emerg market china could grow slower given
weaker execut geopolit issu tariff escal imb
tariff hospit capit budget compress elect year hospit
survey still reflect elev spend bed competitor make inroad
smart medsurg bed launch note us medsurg instal
base penetr centrella today
better buy organ especi discount pt hillrom
lag given frustrat reconcili poor comprehens novel
growth driver lead lack confid sustain growth
organ growth clear path acceler momentum acceler
alreadi evid stock cheap ev/ebitda vs smid peer
rais price target reflect ebitda multipl
support dcf valuat major assumpt includ wacc
termin growth rate peak margin multiple-bas target reflect
discount peer move past non-cor dynam digit solut continu
contribut emerg market show improv discount could
narrow
catalyst like drive debat
 tuck-in like beyond
discount narrow hillrom drive durabl msd growth
discount narrow hillrom drive durabl msd growth
price target reflect ev/ebitda multipl
ebitda discount smid peer given slightli lower growth
bull case ebitda
bull case ebitda
new product growth intern exceed expect cost initi
take margin higher new product launch contribut bp annual
growth margin expans surpass lrp driven revenu upsid mix
cost initi manag remain focus addit deal shift
base case ebitda
base case ebitda
growth stabil mid-singl digit pipelin product move hill-rom
structur organ growth rate msd beyond compani
execut lrp emerg market inflect greater recognit growth
stabil visibl margin improv drive multipl higher
bear case ebitda
bear case ebitda
long-term plan materi organ growth remain lsd
slowdown capital-expenditure environ hurt pss pipelin fail
materi expect initi manifest plan along
top-line shortfal drive limit margin improv
multipl fall lrp fail materi
hill-rom multipl re-rat
growth move higher volatil
decreas hillrom revenu base
diversifi digit new product
launch em penetr drive
hill-rom growth rate durabl
hillrom new lrp call growth
annual om
expans ep compound-annual-growth-rate see
new lrp achiev given product
pipelin remain robust end market
mix digit improv lift margin
hospit budget risk consider
elect year recent alphawis
contribut sale
togeth new launch drive
increment revenu year
lrp
shift connect ecosystem
busi grow strong double-digit
emerg market penetr em
hillrom revenu today ceo john
groetelaar focus drive greater
penetr focus sale
 deal shift wamgr higher
progress cost restructur
risk achiev price
pipelin traction slow fail
materi upcom product
margin leverag prove difficult
materi shift capital-expenditure environ
see similar organ growth profil emerg vs
center around howev differ driver cynosur divestitur
remov key overhang share lead modest multipl expans room
margin accret said still see limit room upsid organ growth
given wamgr remain structur below-p absenc
meaning activ see multipl expans limit given oper
leverag ep growth remain mute beyond cynosur accret remain
underweight increas price target vs prior reflect increas
market multipl
current valuat perform review
valuat current trade ebitda turn discount larg
cap peer prior cynosur divestitur announc share trade
turn discount price target base cy ebitda multipl
turn discount larg cap peer base below-p organ ep growth
absenc moder size see limit room multipl expans given
below-p wamgr limit margin expans opportun
similar profil guidanc cc growth in-lin
expect midpoint organ basi adjust blood
screen ssi see cc growth guidanc nearli mirror organ pre-cyno
divestitur discuss expect similar overal growth profil
differ segment level driver note holog deliv averag
bp top end quarterli cc growth guidanc expect similar
cadenc howev note bp cc beat due blood
upsid may reoccur blood upsid drive bp cc growth
adjust cynosur blood acquisit deliv organ
growth model deceler breast dx
franchis expect slow organ basi includ one quarter cynosur
model growth expect similar beat/rais throughout year
differ segment level driver follow strong year us gantri sale
breast comp becom challeng see growth driven
softwar system upgrad vs gantri placement commentari suggest
capital-expenditure environ remain stabl focal/faxitron acquisit turn organ
drive bp organ growth net expect segment modestli deceler
model organ growth vs diagnost strong year
mdx driven assay approv stronger util viral uptak lead
challeng comp expect materi upsid howev note viral
alon drive bp model growth dx drive bp
corpor surgic remain tale two citi novasure/myosur novasur
continu struggl competit weaker end-market dynam see
myosur growth remain strong new product acceler model
growth surgic see potenti area upsid via new product
increment point surgic growth drive bp corpor prior
divestitur expect cynosur drive bp growth bp revers
math impli pf divestitur absolut growth rate
impact rather growth contribut lost
math cynosur signific margin accret expect assum cynosur
gross margin high expect bp improv gross margin
pro-forma divestitur note increment bp gm
expans guidanc driver primarili new product manufactur
improv model gross margin bp y/i see
potenti upsid assum breakeven/lsd segment oper margin math
impli signific margin accret bp expect note
differ manag commentari point divestitur lead bp
improv state conserv see admittedli level
expans depend expect revenu contribut segment even
assum growth y/i lsd margin would impli bp margin accret
model oper margin bp y/i factor divestitur
asr expect complet see ep accret
transact
still see ep guidanc conserv origin flag ep guidanc
y/i conserv base expect top-line upsid consist
guidanc assum buy-back activ deviat prior year
note holog repurchas averag share past year
deliv averag bp ep growth pro-forma cynosur
analysi impli ep accret divestitur asr discuss
still see ep guidanc conserv bar unforeseen
headwind expect revis higher model ep
growth remain comfort referenc see potenti upsid
driven margin expans bp increment margin drive bp ep
below-p wamgr still pressur growth limit leverag remain
underweight mid-novemb share under-perform med-tech
point despit consist beat/rais throughout year sinc cynosur sale
announc see share risen vs remov
persist overhang taken posit investor still compani must focu
effici capit deploy higher-growth end market shift wamgr
multipl higher beyond see limit upsid organ growth given lower
rel wamgr less leverag given compani alreadi oper
effici om/gm ratio vs peer see account shift peer
multipl updat price target vs prior base cy
ebitda reflect turn discount larg cap peer given slower growth end-
market limit oper leverag opportun continu see
necessari drive multipl higher least deal seem plausibl
note knowledg potenti transact
catalyst like drive debat
competit commerci surgic on-going
price target base ebitda multipl
turn discount larg cap devic peer see discount
warrant given oper slower growth end-market
limit top-line upsid effici structur limit ep
upsid beyond hsd/ldd growth partli driven buy-back activ
breast health diagnost segment acceler drive organ
growth effici alloc capit accret shift
wamgr msd region creat sustain runway
growth cynosur drive materi ep accret augment share
breast health diagnost segment modestli deceler
surgic acceler via new product launch continu myosur
momentum activ necessari fundament shift growth profil
higher leverag limit near-term given current margin structur
suggest effici share buyback continu drive es growth
busi organ growth deceler back region share
gain becom tap breast dx ep growth mute msd driven
limit oper leverag buy-back activ ineffici capit
deploy creat dis-synergi advers impact organ growth
share gain key segment breast dx
nearli tap
compani alreadi oper
effici om/gm ratio vs peer
leverag ep growth like
deriv buyback
see increas activ necessari
shift wagmr higher drive
digit mammographi
system market yet convert
creat ampl runway breast health
cynosur divestitur drive
bp oper margin
and/or share repurchas buy-back
activ drive point ep growth
competit commerci surgic
risk achiev price
deploy capit enter faster
growth end market drive ep growth
greater expect share
breast health dx segment growth
rate acceler
novasur manag competit
threat maintain share
inflect year compani execut dash product
launch shift pharmaci pay-as-you-go model direct commerci
europ post-ypsom see growth sustain beyond
continu drive greater penetr uniqu form factor
payg model break barrier access diabet
path forward horizon clear ide expect see data ada
pre-pivot underway view long term guidanc sale
gm high teen oper margin floor manag beat
current valuat perform review
valuat current trade ev sale premium high
growth smid-cap devic peer price target reflect ev sale
multipl base case premium high growth smid-cap peer
see appropri given growth profil driven penetr
expans shift pharmaci drive sustain growth
inflect year dash product launch shift pharmaci pay-as-
you-go payg model roll-out direct commerci europ expect see
growth model anoth year growth driven
payg shift pharmaci us volum go
pharmaci payg model break barrier access simplic
 form factor drive increas penetr type popul insulet
went patient within total us patient base
expect see trend continu import insulin-
intens popul like least size popul
us view lower competit pump remain less
appeal form factor model us growth repres pt
momentum acceler model reflect materi contribut
horizon sens plan limit launch full-scal
roll-out begin
ex-u traction thu far execut direct distribut transit
europ ypsome anniversari behind us sens
omnipod deliv growth year growth could slightli lumpier
quarter-to-quart given distributor dynam driven lsd sale
impact quarter thu far recent manag commentari
reiter underli demand trend strong fx drove impact
ex us sale expect drive impact
model impact ex us sale see like move cc
growth guidanc well receiv investor discuss
drug deliveri annual busi like continu declin
declin acceler expect moder msd declin
expect anoth invest year fuel continu top-line strength model
bp gm improv follow pt reach lrp
manag commun bring acton manufactur
line on-line put pressur gm expans sens
street remain high oper margin abil
deliv sever point expans question extent
compani reinvest potenti dtc awar campaign sens
manag deploy capit area support horizon roll-out
greater physician patient awar includ type commun net
expect bp om expans follow even stronger year
driven anoth top-line year gm inflect expect see ebit
leverag given gm dynam modest opex increas
expect guidanc expect shift quarterli annual growth
guidanc see shift constant currenc revenu growth expect cc
growth guidanc go year believ manag put compani
posit rais throughout year similar rais guidanc
quarterli model slightli rang cc growth manag may
chang guidanc focu ebitda ebit potenti begin adjust
non-gaap item sbc similar peer sit
ebitda vs street
lrp continu look conserv discuss follow ada see
global healthcar confer see earn see visibl
path increas mark meaning inflect growth
provid evid sustain remain confid manag abil
meet lrp target especi given market expans natur share captur
opportun embed payg shift pharmaci increas opportun
penetr popul model sale impli
top-line growth compound-annual-growth-rate remain confid guidanc mid-
teen om model om rais price target
reflect multipl ev sale support dcf analysi
wacc termin growth rate peak margin
catalyst like drive debat
dash payg model roll-out on-going
long-term omnipod growth sustain
long-term omnipod growth sustain
remain comfort revenu
growth omnipod continu penetr
insulin-intens diabet popul
given eas use form factor
access us pharmaci
path revenu clear
driven channel shift pharmaci
payg model ex us growth expect
horizon launch late
price target reflect ev sale multipl
base case premium high growth smid cap peer
ev/sal support dcf analysi
ev/sal support dcf analysi
ex us reacceler underli growth payg model
shift pharmaci acceler us growth ap competitor prove market
expans immateri omnipod growth greater scale oper
effici pharmaci channel drive om next
ev/sal support dcf analysi
ev/sal support dcf analysi
us growth remain driven shift pharmaci payg
model ex-u grow high-teen mdi pediatr
posit insul omnipod ap competitor risk remain path
sale gm clear like floor horizon ap
launch late
ev/sal support dcf analysi
ev/sal support dcf analysi
pediatr mdi adopt pharmaci shift fail off-set competit
headwind dash horizon adopt modest ap timelin slip path
greater profit becom less clear greater invest requir
medicar shift
pharmaci sustain us growth direct
path profit improv
direct distribut ex us shift
pharmaci us
dash roll provid
foundat cgm integr ap
dash roll-out shift pharmaci
horizon ap data ada june late
risk achiev price
market share ap competitor ii ex-u see
volatil follow move away
path sustain profit becom less
acceler direct distribut ii
disclosur addit drug deliveri deal
ii greater abil drive manufactur
overweight intuit surgic price target procedur
system growth remain strong leav us confid growth sustain despit
competit enter market continu see intuit
maintain technolog leadership materi expand top-line
estim remain consensu see upsid street number view
impact hernia japan china ion sp fulli appreci spend
remain focu see moder om compress rel
support above-consensu ep estim
current valuat perform review
valuat intuit surgic inc current trade ep
ebitda estim respect equat premium price-to-earnings
premium ev/ebitda vs larg cap coverag believ premium justifi
expand given intuit expans potenti strong balanc sheet
faster top bottom line growth vs large-cap coverag
see three way intuit break-out year intuit drive procedur
growth acceler unexpect pipelin announc delay
competitor launch timelin see catalyst see number one like
intuit lag devic ytd driven invest pressur
margin idiosyncrat issu gener surgeri capac sp/china delay
competit fear net see perform expect intuit
catalyst-rich year key catalyst sp china recov earn
outlook understood procedur may acceler simpli backdrop better
expect acceler net placement growth china sp off-set leas
trade-in headwind model gross system placement vs
driver includ sp us ion china placement
follow tepid roll-out oper leas gross placement
increas model vs increment leas activ
drive hit revenu pt growth although off-set system
placement procedur growth yield total revenu growth year
increment driver leas may ex us continu assum trade-in peak
model y/i declin fewer trade-in drive higher
model y/i asp growth procedur growth sit y/i
slightli lower vs y/i procedur growth account slower sp ion
china procedur pull-through ion roll-out ramp though
ion number come system placement see precis
data like import drive broader commerci adopt sp
expect traction even without indic like
could sourc system upsid next year adopt go
pronounc procedur pull-through driver
procedur growth acceler system import procedur remain
valu driver model procedur growth see acceler
possibl driven factor discuss concern gen surg slow may
misplac capac dynam describ improv year-end
three dynam key year ahead cholecystectomi
bariatr play signific role intuit penetr chole
penetr bariatr bariatr may move specialti broad commerci
chole traction inflect japan momentum could continu follow
reimburs expans china placement could catalyst
given higher util net model reflect revenu per procedur
procedur pace anoth stabl year acceler could drive share
expect margin declin moder although intuit like
shi spend aggress see margin step materi
fourth consecut year expect expans revenue-growth-to-opex
growth ratio remain comfort
bp om contract adjust jv step see opportun
modest leverag across year expect interest incom tick slightli
lower rate model vs tax bp lower net
model ep repres ep growth
overcom competit wall worri sens financi impact
competit like limit said sentiment remain key factor
dynam focu includ cmr alreadi launch europ like
see us approv current review expect
present acut near-term threat see thought post robotics-day
compani plan file ce mark impli potenti early-
european launch sens us approv launch month
away intuit focus invest window acceler instal
base leasing/usag base model drive geograph expans ramp ion/sp
reiter overweight dcf-driven pt rise valuat framework reli
heavili out-year growth termin valu rather near-term ep remain
construct phase still drive signific growth
compani scratch surfac phase build foundat
phase detail phase orient thesi see look iri
dcf-deriv price target rise key assumpt includ wacc
termin growth oper margin
catalyst like drive debat
expans procedur momentum drive valu creation
expans procedur momentum drive valu creation
price target base discount cash
flow model assum wacc termin growth rate
long-term oper margin
gener surgeri ex us procedur acceler adopt gener surgeri
ex us geographi two larg under-penetr market pick
materi near-term manag execut materi buyback drive
earn growth higher earli sp ion adopt build investor enthusiasm
dcf base analysi support base case ep
dcf base analysi support base case ep
steadi procedur growth expand see mid-to-high teen
procedur growth partial off-set util growth increas leas
activ mix increas invest pressur margin cost
reduct leverag allow modest oper margin expans
manag use buyback augment earn growth
procedur growth moder competit intensifi visibl toward
product offer launch time concern investor pressur growth
margin expect procedur growth drop low-to-mid-teen level
recent momentum dvh dvp hernia ex us hold oper
margin drop intuit invest heavili ahead competit
launch mix becom larger headwind anticip
trend procedur improv
leav us confid sustain
revenu growth intuit overal
procedur growth acceler
margin sustain low
improv trend procedur
placement allow margin
remain elev even invest increas
prepar competit
pipelin expand sp
system open natur orific singl
incis market ion system open
endolumin market primari focu
lung biopsi treatment
us hernia total procedur drive
pt procedur growth growth
ex us procedur drive pt
updat augment realiti imag
risk achiev price
gynecolog urolog growth materi
competit medtron
see solid catalyst path ahead full commerci roll-out increas sale
forc product data catalyst emerg beyond screen-
af mstop guard-af expect roll-out key revenu growth
driver alongsid continu strong momentum xt manag could
add rep continu build zio footprint continu recogn
competit view expand inclus asymptomat
support one player profit like come focu come
break-even becom clearer horizon pt prior
current valuat perform review
valuat irhythm current trade ev/sal multipl sale
high growth peer think justifi given peer growth outlook
larg under-penetrated price target deriv dcf base
valuat reflect ev sale
strong growth still sight irhythm track toward sequenti improv
top line growth reach revenu growth moder
previou level exist solid catalyst path ahead full
commerci launch octob contribut pt growth assum
revenu base note xt ramp alon deliv growth
assum comp stabil exclud bristol upsid discuss compar
growth last year leav us encourag estim ii
numer studi data catalyst provid support growth name screen-af
data expect intern stroke confer mstop data expect
bristol studi data expect continu
invest salesforc expans possibl primarili us hire
rep throughout limit ou activ continu believ
competit impact mild import keep mind cash requir
scale materi barrier entri irhythm like reach profit break-even
least quarterli run-rat revenu invest hundr
million dollar reach profit servic support effici infrastructur
accuraci report well end-to-end solut associ xt soon
verili asymptomat field
sens compani like guid top line
y/i bracket street xt like repres
number includ upsid associ bristol studi
would includ guid rang believ bristol-rel revenu upsid
compani focus clinic data
increment revenu expect compani call piec becom
materi note could broken guidanc earli mid
estim point
reimburs catalyst earli follow ama panel minut releas
octob highlight accept dual set code repres
posit develop reimburs process derisk bear case
cross walk holter event monitor rate step ruc meet januari
follow rvu recommend mid-februari expect
minut ruc meet publish late februari although
standard timelin releas releas propos rate juli
final rate novemb go effect januari beyond
code chang remain comfort compani abil shift
reimburs mix toward direct model end
continu accret averag asp estim
emphas remain bigger revenu driver
multipl data set could support expans compani expect data
releas beyond includ screen-af data stroke confer
mstop data bristol studi aim asymptomat like
readout given endpoint see guard-af note expect
readout key catalyst expans espeic asymptomat
focu shift toward profit expect pace gross margin expans
modest still see move mid-year sens
compani could add bp end major expans
driven scan time improv partial off-set drag roll-out
expect quicker dissip offset impact rel similar dynam
xt ramp see compani er conserv side guid
gross margin attribut verili expect asymptot lower end
rang haircut opex model increas opex
organ note key contribut factor profit improv
includ invest idn sell penetr revenu cycl manag
project profit break-even
overweight thesi rest sale well growth momentum continu
view favor underserv includ larger asymptomat
popul vs symptomat thesi continu underpin sale
momentum driven primarili xt ii expans post-abl monitor
asymptomat market iii drive cross-sel xt account well
expans follow octob full commerci launch rais pt
roll forward dcf multipl analys base ev sale
multipl support dcf
catalyst like drive debat
on-going roll-out zio potenti materi guard-af trial revenu
path ebit profit break-even
irhythm disrupt technolog grow end market expans
technolog grow end market expans
irhythm zio pois disrupt
technolog larg grow market
ambulatori electrocardiogram monitor
us better diagnost yield cost
irhythm success penetr
exist ecg monitor market
multipl catalyst total address
market expans new product launch
indic expans effort
price target reflect multipl base
case sale repres discount fast growth smid
cap devic compani support dcf valuat assum
wacc assum sale grow driven continu
zio penetr ambulatori ecg market
irhythm see faster market penetr addit upsid new
indic ex us expans stronger zio traction due increas sale
forc effici robust insur coverag reimburs push
investor valu busi higher multipl line peer group
dcf base equat ev/sal
dcf base equat ev/sal
irhythm abl reach low doubl digit penetr us ambulatori
ecg market drive sale
irhythm face slower launch tougher competit scenario us
market share reach high singl digit end valuat
multipl contract investor appli multipl discount peer group
irhythm current penetr us
ambulatori ecg monitor market
dilig among physician use zio
suggest potenti util doubl
exist provid next year
irhtyhm extens databas continu
ecg data data curat abil provid
data qualiti cost advantag peer
on-going roll-out zio potenti
materi guard-af trial revenu
path ebit profit break-even
screen-af mstop data
risk achiev price
multipl competitor on-going effort
develop product solut mount
competit respons irhythm zio
investor limit visibl
manag effort drive expans
via new product introduct indic
on-going invest drive market
penetr may lead futur capit rais
 invest thesi look attract multipl regulatori
action aim control pharma price reflect pharma growth
like acceler histor lift multipl
portfolio balanc consum stabil md come six
consecut quarter momentum improv structur mani concern
address consid stock appear price significantli
legal liabil probability-weigh analysi suggest see
defens return result multipl expans out-performance
upgrad overweight rais price target vs prior
base msd discount price-to-earnings multipl see get back defens
current valuat perform review
valuat current trade ntm price-to-earnings discount point
wider vs histor discount discount widen peak premium
decemb discount current point move mainli
due litig liabil overhang pharma multipl compress agre
 trade discount given factor mid-teen
discount overdon discuss see mid-single-digit discount
appropri impli price target base ep
look defens divers three-way street april note
portfolio increasingli weight pharma would drive multipl compress
sinc valuat discount expand nearli widest
decad pictur evolv multipl regulatori action aim
control pharma price reflect pharma growth like acceler
histor lift multipl portfolio
balanc consum stabil medic devic diagnost md
busi come six consecut quarter momentum improv structur
mani concern address consid stock appear price
significantli legal liabil probability-weight analysi suggest see
 defens return result multipl expans out-performance
legal liabil risk/reward look favor opioid talc litig
domin debat rel valuat multipl vs move
peak trough less year adjust pharma multipl
contract market may price pre-tax legal liabil
npv stock price impact analysi suggest even bear case scenario
legal liabil npv impact would per share market
significantli over-estim aggreg legal liabil view see
current valuat discount vs unwarr averag
base case bull case estim legal liabil
respect per share impact pleas see legal liabil bear case
reflect deep-div analysi legal liabil calcul
pharma growth stock highli correl bottom-up
analysi leav us confid acceler driver includ eas
headwind blockbust indic expans pipelin pharma
headwind eas year drive growth
trend carri anniversari zytiga see tailwind blockbust
franchis stelara darzalex imbruvica sale like outperform
street drive point pharma growth pipelin driver
tremfya spravato balversa erleada drive bp driven share gain
indic expans rais pharma outlook street
drive growth see upsid number note everi point
pharma upsid bp corpor pleas see pharma acceler drive
multipl addit detail
balanc profil emerg ceo gorski reli heavili
pharma earli tenur catch pharma price headwind miss devic
innov view see exhibit capit deploy analysi sinc
compani taken activ approach portfolio manag lifescan asp
etc cut cost agreement driven md growth flat trough
growth even pharma acceler progress evid organ
growth project come pharma vs averag sinc
md growth continu show momentum model md growth
drive bp corpor consum perform line
market net model impli corpor organ growth vs
pleas see balanc growth portfolio fare sum-of-the-part
sotp valu meaning higher upgrad overweight ntm price-to-earnings
valuat trade discount nearli widest discount
pt wider averag discount sotp
analysi yield price target upsid despit sever pocket
conservat includ segment margin expans modestli conserv
segment multipl see exhibit upgrad overweight view
legal liabil reflect valuat pharma drive acceler
balanc approach portfolio risk call includ
legal liabil greater bear case remain overhang
slower ramp pharma pipelin product deceler consumer/md
franchis rais price target vs prior base
ep discount vs
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig ip prosecut talent trial proceed
locat juri composit judg examin composit investor contact
legal advisor issu law relat subject matter materi
catalyst like drive debat
progress on-going litig process particularli opioid talc
pharma pipelin launch line extens trial read-out
price target base multipl
base case ep support sotp analysi assum
trade mid-single-digit discount given growth
acceler pharma improv fundament
consumer/md balanc litig overhang
bull case ep
bull case ep
pharma organ growth acceler high-singl digit md
consum demonstr momentum oper leverag gener lead
sustain dd ep growth make progress litig process
overhang gradual remov share aggreg legal liabil
 trade valuat in-lin slight premium
base ep sotp-support
base ep sotp-support
blockbust franchis pipelin launch contribut pharma
acceler drive multipl margin higher md continu
modestli acceler consum stabil in-lin market
growth aggreg legal liabil valuat disconnect vs
narrow progress toward legal settlement made
bear ep
bear ep
competit threat biosimilar eros continu lead lsd/msd growth
pharma md consum deceler y/i segment revers cours
 leverag limit driven incom gap neg newsflow
opioid talc risperd continu weigh share aggreg legal
liabil total trade discount
litig liabil
reflect share view creat
meaning valuat disconnect vs
pharma-driven acceler pois
drive multipl higher led
blockbust franchis pipelin launch
momentum md consum
segment drive balanc
growth profil less reliant
progress toward litig settlement
drive narrow discount
blockbust pipeline-driven launch
drive pharma acceler point
increment pharma growth drive bp
md consum segment
demonstr sign improv
segment pois acceler
progress on-going litig process
particularli opioid talc
trial read-out
risk achiev price
greater anticip
pharma pipelin unabl off-set
biosimilar competit risk
turnaround consum md fail
materi occur slowli
bia becom posit past sever quarter given remov
guidanc headwind conserv outlook emerg pipelin sens
growth back half load see
organ growth improv momentum acceler given
pipelin launch contribut discuss view consist execut
durabl top bottom line perform key becom posit
await emerg trend late rais price
target ep continu reflect discount
large-cap peer
current valuat perform review
valuat current trade ep discount larg cap
peer ebitda believ price-to-earnings multipl group
appropri given execut improv last sever month bring
us pt
expect strong close continu expect organ growth
vs model prior estim guidanc could come
diabet come off-set spine tavr
diabet guide-down addit bp headwind would
need increment revenu bridg top-end new guidanc
growth year extent see extend spine strength addit
tavr upsid top rais cvg guidanc micra av launch ahead
schedul drive revenu bull-cas scenario specialti
therapi in-lin model reflect interstim headwind axon
entranc market question stack basi
guidanc year reflect nearli pt momentum deceler back
half although stack basi normal comp follow
outag hurrican maria guidanc impli bp back-half momentum
earn leverag back-half continu expect show
y/i gross margin declin due currenc china tariff model
year view hold oper margin guidanc
conserv need deliv bp y/i om expans
follow bp expans seen meet guidanc bp y/i om
expans model slightli guidanc om year
interest expens recent guid remain quarter drive
ep tax guid year drive ep could
off-set gm headwind still see path ep growth
year expect flat slightli modest om expans
pipeline-driven acceler manag consist messag around
pipelin subsequ acceler hard miss guidanc impli
limit impact pipelin driver begin contribut current
model bp organ growth improv pipelin catalyst includ
cvg begun see sign low-risk tavr inflect y/i
tavr revenu ww expect continu upsid
remaind driven on-going expans new center
reveal linq insert cardiac monitor micra av transcathet pace
system track launch later recent detail potenti
financi impact micra av see could drive
growth respect separ dcb headwind
anniversari march expect return msd growth
mitg plan launch surgic robot ex-u late plan
file ce mark us launch like month away see
thought septemb analyst day
diabet like remain pressur launch
track late follow data present attd februari
recent instat pump revenu deferr system similar
program prior could help hold current patient instal base
product transit key consider includ recent
innov impact deferr time assum hsd diabet growth
growth still reflect pt momentum
rtg mazor pull continu drive spine expect trend
continu in-lin snm model interstim micro launch
late earli believ continu strength mazor coupl
interstim sens db platform launch drive acceler
understand extra sell week dynam extra sell
week dynam compani see everi year given compani uniqu
fiscal calendar dynam last seen week fall
includ week instead week sale lift sale
sale thing constant drive ep
though reinvest like expect highlight dynam
provid guidanc distinguish top-line impact organ growth
acceler consist execut pipelin remain key perform
pt bia posit past sever quarter given
remov guidanc headwind conserv outlook emerg pipelin although
cvg rtg tailwind remain somewhat off-set diabet weak
guidanc impli growth improv next quarter
alway focu given current discount peer ep vs
large-cap coverag achiev outlook still see setup
favor growth improv like continu cours await
emerg trend come quarter rais price target
ep reflect discount large-cap peer
catalyst like drive debat
better execut lead rel multipl expans
better execut lead rel multipl expans
deriv base case scenario price target reflect
base-cas ep discount larg cap
reset expect execut organ growth trend
sustain new launch off-set competit headwind ep growth
doubl digit aggress capit deploy drive upsid
total return profil long-term profil mid-singl digit
organ growth bp margin expans high-singl digit ep
growth total return profil
end market slow take top-line organ growth fall
manag mid-singl digit guidanc underli leverag harder
come given lower growth earn growth reach mid upper
total return profil achiev
consist organ sale growth
least bp ebit margin expans
return back
see organ revenu guidanc
achiev potenti conserv given
comp product pipelin
drive bp annual margin expans
top-line growth estim bp
top-line growth contribut ep
margin estim bp ebit
margin drive ep
new product launch uptak high
neurosurgeri neurovascular
ration margin
risk achiev price
db tavr dcb linq
slowdown acceler emerg
less repurchas activ materi
new platform launch late catalyz acceler share gain
competit risk clinic product perspect well
understood clinic data expand key data pain diabet
neuropathi non-surg back come overweight thesi
comfort rest improv market trend ii unwav compani growth
iii catalyst incorpor commerci initi clinic data rais pt
prior
current valuat perform review
valuat current trade sale estim reflect
discount rel smid cap high growth peer set price target
deriv dcf model use wacc termin growth rate
peak margin equat ev/sal multipl repres
discount versu high growth smid cap peer
track high end guidanc double-digit top line growth view
guidanc conserv high end rang impli pt
momentum deceler quarter implant us grew healthi
underli growth adjust stock quarter line
trend vs without adjust stock destock consid
underli implant trend back half year anniversari
stock effect see estim like conserv omnia
key catalyst late us launch europ australia launch
throughout market model suggest us market see growth
follow low single-digit dip support histor rate modest
new product innov expand label also affirm compani commentari
around confid market pickup note boston deliv
neuromod growth portfolio intact ytd compani commentari
indic continu strong momentum well broader neuromod
portfolio leav us increment comfort market outlook expect
compani guid bracket consensu near low end
estim
expect posit market share trend support robust catalyst
path forecast global share climb bp us share bp
model robust hire activ throughout ad sale rep us
well low double-digit improv per rep product dynam back
half bolster omnia continu us launch europ australia launch
addit partial pdn data nan well potenti
data road could drive modest uptick indic prior label
get cash flow break-even underappreci catalyst gross margin
revers trend expand north see compani guid
expect oper leverag go opex revenu
y/i attribut expect declin given trial
expens roll although could partial off-set product develop
innov effort increas sg compani ration expens
leverag omnia litig boston could continu overhang
appeal court decis expect associ legal fee
like minim expect ebitda near break-even oper profit
break even see compani begin bake earn product
metric guidanc
next compani near-term focu continu regain commerci
momentum launch omnia focu intermedi term like center
reinvigor pipelin mainli although non- rule
maxim ex us focus busi develop compani ampl
cash achiev profit less flexibl pursu think
would opportun sens compani extend expir date
convert note reduc dilut effect share dilut
secur separ deal less like see select opportun pain
manag wireless platform
remain overweight rais pt overweight thesi comfort rest
improv market trend ii unwav compani growth iii catalyst
incorpor commerci initi omnia clinic data pdn rais pt
earn roll-forward sale high single-digit
consensu underpin convict around clear path sustain double-digit
growth pt base ev sale repres discount high
growth smid-cap comp group
catalyst like drive debat
competit launch data on-going
omnia launch launch us late eu australia
price target reflect multipl
base case sale high growth smid cap med-tech comp
materi share gain expans market growth near term
acceler innov new indic progress faster
timelin expect combin better expect share gain
drive sale acceler high teen lead substanti
re-rat multipl
base case sale support dcf base analysi
base case sale support dcf base analysi
inflect headwind omnia launch late
launch lead materi acceler share gain grow
mid-teen expans initi drive market growth enthusiasm
near data readout
growth slow competit headwind less differenti omnia
launch fail catalyz sale less differenti combin upstart
competit execut issu lead growth mid singl digit lead
multipl contract
believ new platform launch
late catalyz acceler share
gain
competit risk clinic
product perspect well understood
clinic data expand key
data pain diabet neuropathi non-
surgic back come
pt increment ww share
pt increment us share
pt increment us market growth
assum pro rata share impli
revenu upsid
competit launch data on-going
risk achiev price
and/or omnia launch fail catalyz
upstart competitor could acquir
and/or obtain fund launch take
invest case progress look attract
driven new leadership consist execut competit
robot offer realist above-consensu lrp target see continu
market growth spine driven puls key upsid driver
robot offer launch see modest margin expans
execut remain key remain equal-weight increas pt
vs prior
current valuat perform review
valuat nuvas inc current trade ebitda estim turn
discount smid cap peer turn discount globu similarli price
target base ebitda see warrant given outsiz exposur
lower-growth spine end-market see room expans compani
acceler top-line drive leverag
setup look favor ceo chri barri deliv consecut quarter
momentum acceler upsid lead point out-performance
vs follow recent perform investor day juli see
becom increment construct
see reason expect deceler tailwind includ spine
introduct particularli am cervic puls discuss
foreseen headwind break trend continu see price pressur
robot gap puls help bridg robot commerci
expect guidanc organ bracket street organ
model organ growth expect upsid core spine puls lesser extent
ampl runway us spine growth driven track deliv
growth us spine year strongest perform sinc manag
attribut success primarili follow new product improv
market see anoth strong year us spine growth similar
driver commentari suggest plenti runway surgeon
convers expect new product cervic deform also tailwind
growth fill key portfolio gap model us spine growth like
prove conserv compani deliv anoth year would add
increment bp corpor
spine like acceler ldd intern growth temper
due limit set avail certain region may persist earli
strateg compani comfort intern strategi
lead core compet xlif drive penetr
next year compani plan enter key region china franc
expect acceler growth toward lrp compound-annual-growth-rate expect
acceler y/i comp becom softer expans ramp model growth
drive bp corpor growth reach in-lin lrp compound-annual-growth-rate
would drive increment bp
puls look like contribut puls nuvas integr ecosystem
spine procedur workflow current beta test commentari
suggest roll-out gradual capac key area focu
focu target placement broader ramp expect expect
revenu contribut becom meaning note modest chang
tone prior commentari howev view concern note
puls system drive bp see puls key driver
enabl technolog gap robot applic commerci
discuss see compani offer competit peer see
expect hear regard commerci plan strategi etc throughout
year
what margin profil margin expect becom key
debat follow investor day juli see commentari allud
heighten invest certain area steril packag mdr puls etc
may weigh margin said manag commit level
expans ramp thereaft back half lrp toward
target expect gross margin stabl suppli chain headwind off-set
manufactur effici see major leverag come sg
commentari suggest point margin expans unlik upsid may
reinvest sustain futur growth support model impli bp
margin expans drive bp ep growth remain comfort
risk reward skew upsid rais pt execut well
new leadership led bp out-performance vs
look see year acceler like driven us spine
stabil intern acceler puls margin remain focu given
compani histori fail deliv margin target remain comfort
trajectori expans lrp expect
activ respect follow mute like focus
enabl tech space note knowledg potenti transact
current valuat ebitda impli meaning turn discount
globu expand mid-teen mid-year rais price target
base ebitda turn discount smid cap peer said see room
multipl expans compani continu acceler deliv top
catalyst like drive debat
new product launch cervical/deform
deriv base case scenario price target base
ebitda estim discount smid cap peer
see warrant given exposur challeng end-market
modestli off-set compani demonstr abil
acceler growth expand margin
us spine growth maintain high singl digit intern grow
high-teen puls eventu robot placement ramp faster
anticip lead long-term pull-through compani drive
leverag via manufactur improv effici drive bp
nuvas maintain mid-singl digit organ growth profil driven share
gain us spine intern penetr puls robot drive upsid
uss revenu gener implant pull-through long-term compani
abl expand margin bp per year drive dd ep growth
spine market remain pressur enabl technolog
progress mute compani continu struggl
manufactur improv sg leverag
investor day set forth
achiev target sever pocket
conservat particularli us spine
real sever driver lead
point margin expans
compani deliv consist
upsid guidanc consensu estim
lead recoveri multipl
point us spine growth worth bp
corpor
puls system placement drive
bp growth
point margin expans drive
point ep growth
new product launch cervical/deform
risk achiev price
robot gap lengthen lose
price pressur amplifi core spine
margin target overli ambiti
shockwav ivl technolog like disrupt larg grow market ivl util
broad vessel bed activ catalyst path adequ reimburs paint
robust commerci pictur near-term valuat present balanc pictur
opportun risk shockwav path growth rest product data
catalyst go set compani long-term
penetr world-wide sizeabl underserv cad pad estim
recogn achiev profit break-even
requir seamless coordin strong growth cost manag
rais pt
current valuat perform review
shockwav current trade ntm ev sale meaning high growth
smid mean pt base ev sale multipl support
dcf use wacc
shockwav deliv better consensu initi coverag
shockwav earlier year thesi shockwav uniqu posit
leverag expans tam market share assumpt remain conserv
estim repres modest penetr across
atk btk coronari vessel pois tripl revenu
expect compani ride wave product data catalyst
top line chief among btk primari driver revenu inflect
growth cad expect readout
revenu driver expect approv us
project by-vessel bed market penetr reach atk
btk coronari note track week
away year-end leav us encourag expect penetr
level atk btk coronari respect target
achiev feel confid around btk momentum construct earli
feedback ivl adopt trend model ww btk sale
growth back btk estim impli core
growth leav us encourag growth figur
impli y/i declin averag revenu per rep
impli improv rep product would deliv upsid model
indic revenu per rep impli compound-annual-growth-rate
level view achiev
net growth curv steep encourag traction see two
catalyst btk coronari drive upsid estim
walk dynam length healthcar confer recap see
initi report see
coronari invest drive opex higher shockwav complet secondari equiti
deal pull forward invest coronari essenti compani begin hire
rep upon complet cad enrol pull forward margin
compani bp gm climb expect back half load driven
combin full-scal coronari product ii offshor chunk
compani manufactur effort iii offset impact process partial
slow on-going to- capac expans process expect
compani end year rep expand end
balanc sale specialti rep count result expect headcount add
take anoth front also
ad anoth current estim get given meaning
trail expens pad cad iv core spend pipelin off-set
upcom conclus cad continu feel good shockwav
achiev ebitda profit break-even larg line prior mode
break catalyst buzz around btk viva follow physician
enthusiasm tct leav us encourag uptick broad util btk
full launch could drive close growth allow btk ww sale
reach bd lutonix btk delay could bolster pace ivl adopt like
throughout critic limb ischemia treatment option remain limit
common treatment algorithm primarili bypass amput coronari enthusiasm
see like escal anticip cad readout tct
underpin coronari contribut growth pad resum
estim enrol complet data project rep count
increas hire activ heavier clinic specialist side
expect compani guid mid point consensu
remain equal-weight shockwav disrupt technolog pois quick
adopt larg pad cad market investor look farther futur
given signific perform stock sinc ipo suggest greater comfort
market develop physician adopt remain equal-weight driven
valuat reflect balanc pictur signific opportun risk
view could chang given potenti technolog pend increment
dilig suggest faster assum adopt ivl greater longer term
util increment data point de-risk commerci execut clinic risk
shockwav tripl sale infrastructur next pad
cad data posit first-in-man data tavl rais pt
base sale multipl support dcf assum
wacc perpetu growth rate
catalyst like drive debat
lx cathet updat expect launch
shockwav adoptt driven ivl valu proposit larg cad pad
shockwav adoptt driven ivl valu proposit larg cad pad
price target reflect multipl
base case sale larg line high growth smid cap
devic compani support dcf valuat assum
wacc penetr atk btk coronari vessel
bed assum sale grow compound-annual-growth-rate
driven ivl differenti clinic econom valu proposit
shockwav momentum inflect faster expect sale expect
revis higher relaunch begin contribut sale growth
larg bore adopt drive broader util atk ahead expect
gain broad traction europ despit limit reimburs suggest fast
ramp us launch reimburs less concern valuat
multipl expand given longer term expect multibillion dollar market
ev/sal support dcf
ev/sal support dcf
shockwav begin drive market adopt ivl given eas use abil
treat hard reach calcium better peer safeti profil
relaunch btk show sign traction broader adopt
coronari cathet continu gain traction europ
atk cathet adopt larg bore tavr/impella procedur
reimburs ev/sal multipl larg line peer group
justifi shockwav peer growth prospect
physician adopt expect sale revis lower
reimburs prove greater concern especi europ light limit
longer term data limit adopt valuat multipl contract still
repres larg multibillion dollar longer term growth prospect
shockwav provid ivl cathet
cad pad market
compani differenti offer given
eas use abil treat calcium
safeti profil posit compani
drive adopt multipl vessel bed
estim impli msd penetr
intermedi term risk adjust
earli stage commerci
reimburs suffici vessel bed
ivl key valu proposit
notabl coronari btk larg bore
relaunch drive
ww sale growth us launch drive
ww sale growth
bp us vessel bed penetr
impli addit dcf valu
pad cad data drive physician
adopt possibl guidelin discuss
gross margin doubl
lx cathet updat expect
risk achiev price
channel develop occur faster
slower pace physician adopt
less limit lead greater lower vessel
cad data posit delay us
reimburs prove less
rate limit util expect
patent litig csi result
ivl
overweight price target invest thesi
rest compani abil acceler top-line result signific
commerci invest occur surgeon train program
continu well attend aid modest increas payment
rate follow mute perform lack materi upsid
quarterli number investor look inflect year
current valuat perform review
valuat si-bon current trade sale estim notabl
turn discount high growth smid-cap peer like due materi busi
acceler forecast proven exposur lower growth
end-market price target deriv dcf valuat reflect
sale estim nearli in-lin current trade level consist upsid
deliv see multipl expand compress discount peer
see base busi acceler sever driver leav us comfort
continu acceler inflect year growth anticip si-
bone increas sale forc hire rep css
surgeon train program remain strong compani like add activ
surgeon y/i payment increas see drive addit surgeon
interest consist survey potenti upsid driven commerci payor
coverag bedrock revenu discuss net model us revenu
y/i impli revenu per matur rep assum si-bon add
sale rep note would impli increas y/i rep
product vs current model may prove conserv revenu
per rep would impli annual revenu upsid expans
primari focu compani expect growth improv given
germani commerci headwind anniversari still expect segment grow
modestli behind us model drive bp growth expect
guid y/i impli stabil bottom end point
acceler top end model revenu y/i remain
bedrock upsid driver discuss ifus bedrock key focu
year nass real driver associ trickl effect see
occur deform surgeon stabil si joint bedrock prior
larger deform case open opportun becom train
center next two year begin expect readout
see bedrock revenu ramp
point growth although primari driver busi bedrock
key driver upsid number
outlin payor catalyst si-bon announc public ifus data
septemb see flag could key gate item
larg commerci payor re-review coverag polici mi sijf posit
revis coverag polici mi sijf last week see ad cover
live manag commentari suggest convers progress well
expect larg payor review polici regularli schedul timelin note
aetna schedul review polici januari like mid-
year tbd forecast addit payor coverag
model note addit larger payor would add addit
cover live howev given coverag polici sijf typic involv
conserv treatment prior fusion expect impact
spend growth like moder hire continu set record
year hire compani set add sale rep clinic
support specialist css manag commentari suggest hire expect
steep commerci expans continu prioriti
compani plan exit rep/css ratio view ratio hold
model addit rep css bring total sale
forc model total opex y/i
expens expect grow within due silvia clinic trial
initiation/enrol like burn anoth cash
incorpor equiti financ model
cash reach trough earli
await top-line acceler follow point rel under-perform
challeng year investor delay invest led
growth transit year rather materi growth inflect investor initi
expect said growth acceler absolut basi past
three quarter momentum half-year basi improv sinc
combin commerci invest surgeon train program
reimburs payment improv label inflect year current
valuat sale trade turn discount compar
growth smid-cap price target base dcf-analysi impli
catalyst like drive debat
updat coverag polici commerci payor on-going
expand exclus contract ifus triangular-bas implant on-going
price target base dcf valuat
similar spine compar price target impli
multipl base case sale premium core
spine compar given outsiz growth discount high
growth smid cap devic peer given acceler busi
yet proven
si-bon abl gain posit coverag decis larg commerci
payor develop addit exclus contract physician reimburs
doubl level compar open si joint fusion drive adopt
procedur growth faster anticip si-bon achiev market
penetr revenu
signific invest commerci expans surgeon train drive
top-line acceler increas physician payment rate
result increment interest surgeon perform procedur si-bon
abl gradual add commerci payor coverag next sever year
increas total ifus cover live
si-bon unsuccess gener addit coverag commerci
payor physician interest remain mute given payment rate still
compar procedur price pressur intensifi due increas competit
achiev market penetr
advantag penetr underserv
sacroiliac joint fusion market
differenti surgic implant ifus
implant random control studi
busi near point inflect
given momentum reimburs
landscap ii continu focu surgeon
educ iii sale forc expans
contribut meaning
addit pt penetr drive
pt growth
traction commerci payor present
opportun expand cover live
attract gross margin profil
expans patient identif
opportun deform trauma
updat coverag polici addit
expand exclus contract ifus
risk achiev price
inabl gain addit reimburs
coverag commerci payor
rel low reimburs vs
si joint fusion market develop
expect oper small nich
limit visibl pipelin effort
durabl premium growth consist theme expect
continu driven continu mako penetr medsurg durabl
spine/neuro acceler key invest debat surround investor would
see greater level margin expans wright medic
acquisit like push year caus contract multipl despit
remain overweight stryker given organ growth upsid like
consensu model signific deceler y/i dd ep growth
still like potenti pocket upsid increas pt vs
current valuat perform review
valuat current trade ep ebitda
estim respect premium larg cap peer price-to-earnings ebitda
note sinc wright medic acquisit multipl contract valu
ep reflect two turn premium larg cap peer justifi
durabl premium growth profil balanc sheet opportun
deliv year organ growth improv deliv
growth bp momentum acceler would impli growth
consecut year organ growth improv turn key debat
becom long continu recent commentari notabl posit
regard prospect absenc idiosyncrat headwind current
foreseen see reason grow in-lin bottom-up
basi see orthoped growth rel stabl medsurg slightli
deceler may prove conserv spine/neuro acceler discuss
see emerg market cost initi next leg transform
ceo kevin lobo although latter like temper given
acquisit discuss consist expect top-line guidanc
see deliv durabl growth context
guid januari consensu model closer organ growth
track deliv close current consensu estim
forecast sever deceler y/i uniqu discrep vs larg cap
growth name model impli organ growth expect upsid throughout
year consist
mako hip intern launch greater driver mako penetr
knee see plenti runway continu market growth/shar gain
core knee follow growth see modest deceler model
organ howev recent commentari discuss ex us addit growth
engin sold mako system japan china approv like
near-term beyond knee see mako hip signific driver
commentari suggest y/i growth mako hip hip momentum acceler
bp ww penetr us see ampl runway mix-driven
growth closer deal close like provid clariti
time mako extrem applic dont see driver note
revenu current includ model deal expect
close consist practic revis trauma/extrem
growth account potenti sale forc disrupt interim
previous expect segment acceler given supply-driven issu year
alpha creat easier comp model impli growth stabil point
growth drive /- bp ortho growth net model ortho growth
medsurg durabl continu discuss extens flaw investor view
stryker medsurg segment cyclic busi given segment post
corpor acceler growth year past year follow sale
forc split instrument growth track low-double-digit year creat
challeng comp howev still see hsd growth like driven invuiti
becom organ bp instrument commerci momentum continu
endo like acceler camera enter year launch model
growth drive bp medsurg plan launch new lifepak first
year new bed first year expect key driver growth
detail scant thu far net model medsurg growth like
prove conserv see reason expect deceler increment point
medsurg growth drive bp corpor
spine neuro expect acceler spine perform expect
expect given earli integr challeng acquisit
turn organ easier comp set segment acceler
integr challeng anniversari recent manag commentari
point msd organ growth remain slightli cautiou
increment point spine growth drive bp upsid corpor
confid neuro acceler sheath technic issu resolv earli
decemb compani larg bore aspir like launch medtron
commentari suggest compani reach market share
aspir market contribut recent market growth
ischem stroke captur pt share drive
bp neuro growth model organ growth neuro bp corpor
see potenti upsid compani deliv averag past
wright acquisit pressur optimist could start see
 leverag given acceler top-line bp margin
commit ep floor deliv averag sinc commit
compens chang erp traction howev upon announc
acquisit manag back bp margin commit given
expect dilut reiter ep floor despit forecast
dilut see said compani beaten initi midpoint
guidanc past year dilut could off-set number
factor vs origin deal model includ top-line upsid
favor interest rate debt bp favor deal model impli
ep increment synergi synergi
ep thu expect dilut could view conserv although
earli tell still see dd ep growth like onward major
come top-line given recent commentari see ep growth guidanc
like model impli ep y/i modestli street
setup attract despit wright medic overhang remain overweight stryker
recent capit deploy via mobiu
favor acquisit end-market growth rate structur lower
typic acquisit strategi deal return accret near-
term said disrupt dilut alreadi reflect stock
recent perform strateg rational behind mobiu defens
integr imag state previous wright medic insignific
overhang share given minim return profil like dis-synergi associ
dilut see despit maintain favor view given
see meaning upsid consensu estim forecast point organ
growth deceler y/i recent sell-off provid attract entri point even
adjust dilut updat price target base
price-to-earnings pf two-turn premium larg cap devic peer in-
line modestli high growth larg cap given rel lower leverag
impli ebitda pf turn premium larg cap peer
catalyst like drive debat
capit deploy buyback on-going
deriv base case scenario multipl two-turn
premium larg cap peer see warrant given
durabl premium growth profil howev modestli larg cap
growth peer given leverag ep growth limit
organ growth acceler eighth consecut year
 dilut wright medic acquisit mitig top-line upsid
synergi drive margin back bp annual share servic
opportun erp implement drive mid-teen earn growth
organ growth remain durabl driven mako penetr medsurg
durabl spine/neuro acceler margin expans like minim given
wright medic dilut ep growth like remain
organ growth slow point y/i driven downturn capit cycl spine
disrupt ortho competit margin progress remain mute driven
ineffici dilut
deliv consecut year
organ growth improv
potenti growth
durabl key theme driven
mako medsurg durabl acquisition-
mako penetr still earli
knee hip provid ampl
runway mix benefit share gain
materi expans near-term
maintain commit ep
mako driven consecut year
market growth ww knee average
point market
medsurg growth durabl point
medsurg upsid drive bp growth
share servic opportun erp
implement provid opportun
margin expans bp margin expans
drive point ep growth
capit deploy buyback
risk achiev price
organ growth deceler y/i closer
wright medic dis-synergi dilut
greater forecast
competit environ ortho robot
remain posit durabl growth margin profil
driven neotract manta core consist compani materi
improv abil deliv consist organ growth stabil drive point
out-performance see organ growth guidanc like
consist initi long rang lrp expect upsid
throughout year toward rang margin bridg remain steep
clear view sustain mid-teen higher growth
remain overweight increas pt vs prior
current valuat perform review
valuat current trade ep ebitda
estim respect repres turn premium larg cap peer
turn premium larg cap growth peer see premium valuat warrant
given premium organ ep growth profil valu
ep estim repres four turn premium larg cap peer two turn
premium larg cap growth peer
posit growth durabl teleflex perform includ three
consecut quarter organ growth momentum acceler driven part
neotract vsi drive point growth anniversari idiosyncrat issu
percuv recal trocar divestitur etc reduc north american distributor
relianc discuss durabl continu key theme
driven neotract manta broader busi stabil see recent ceo
meet see organ growth guidanc like consist initi
long rang lrp expect upsid throughout year
toward rang see organ growth bridg neotract drive
point vsi drive point base busi deliv point
manta key swing factor discuss
neotract runway appear sustain see neotract momentum continu
base sever factor includ competit impact rezum nomin
reimburs remain favor see dtc market roll
broadli hire remain strong although urolift roll-out
delay vs origin estim see concern given
broader segment momentum manag allud sever clinic
studi plan ad exist urolift data arsen see primari
area focu competit studi vs rezum potenti indic front-lin
therapi compar vs drug see segment guidanc like
conserv drive bp growth note initi guid neotract
growth subsequ rais twice current expect similar
cadenc model neotract growth drive bp growth note
segment growth would drive increment bp corpor
manta key swing factor healthcar confer manag
discuss penetr aggress assumpt talk
origin sale estim see convers suggest price
like land rang see reason like
barrier broader adopt competit vivasur potenti terumo
like factor may enter debat year time model impli
manta revenu drive bp growth see
achiev share note manta upsid drive bp growth
path margin steep clear assum midpoint guidanc margin
ramp lrp impli bp year date fx tariff
pulled-forward invest neotract/manta impact margin bp
impli underli expans point year along improv mix
cost restructur leav us comfort model margin bp y/i
see detail drive pt ep growth see ep guidanc
ep y/i bracket street like expect upsid
throughout year remain comfort model ep
consensu note beaten ep averag year
expect similar pattern driven top-line upsid point top-line upsid
drive pt ep
 like come back debat clear creat
signific sharehold valu sever key acquisit year notabl
lma vidacar vsi neotract manta follow deal like
activ year plausibl see activ like size
revenu per manag commentari recent commentari
suggest willing acquir anoth neotract/vsi size asset
environ like conduc near-term closer proxim elect
manag suggest take net leverag vs current impli
deal could doabl right opportun aris strateg see
compani continu deploy capit wamgr-accret end-market
vascular surgic potenti area interest
consist key rais pt overweight thesi predic
above-p revenu ep growth profil support premium valuat
larg cap peer remain posit bias structur growth margin profil
expect upsid consensu estim see margin
expans ramp via sale mix improv cost save initi
anniversari variou one-tim dynam turn see mid-teen earn
growth sustain forese futur warrant premium valuat
rais price target vs prior base price-to-earnings two-turn
premium larg cap growth peer given compar organ growth profil
catalyst like drive debat
rezum competit reimburs chang on-going
incorpor restructur program on-going
 activ balanc sheet deploy on-going
price target base ep four-turn
premium larg cap devic peer see justifi given
outsiz organ growth margin profil
investor look organ growth acceler
neotract momentum continu manta traction build higher margin
busi neotract intervent etc drive pt gross margin expans
annual restructur program gener busi leverag lead
pt oper margin expans abl drive
high teen ep growth sustain
organ growth stabil like driven neotract core busi
stabil like drive growth manta remain key upsid
driver potenti drive bp favor product mix cost program
drive pt margin lrp impli mid-teen earn growth
neotract momentum slow competit pressur rezum intensifi
onward busi growth return distributor predict
becom challeng organ growth retreat mid singl digit
non-underli headwind pressur margin reach lrp
organ growth profil
maintain durabl driven
neotract vsi manta core busi
lrp margin target appear steep
variou factor includ sale mix cost
neotract growth margin potenti
greater guidanc consensu
organ growth profil acceler
neotract contribut pt
manta revenu
translat addit pt growth
dtd convers restructur
program drive high teen ep growth
rezum competit reimburs
incorpor restructur program
 activ balanc sheet
risk achiev price
materi delay
reach long term margin target core
busi restructur program fall
neotract competit intensifi rezum
success take market share
new product launch acquisit fail
deliv meaning financi contribut
transmed oc pois disrupt organ transplant space seen
limit innov standard care transport preserv
donat organ remain rudimentari cold storag thesi rest risk-
adjust penetr sizeabl ii seri potenti construct
clinic data regulatori catalyst oc show earli sign traction amongst
kol hospit onboard physician train reimburs challeng
shift clinic commerci present challeng take time work
drive equal-weight rate pt stay
current valuat perform review
valuat transmed current trade ev sale present discount
high growth smid cap peer set see multipl risk could impact
compani growth trajectori stage pt support dcf
wacc impli ev sale multipl repres discount high
growth peer group larg line low end rang
achiev revenu project transmed reach top line
driven solid growth across lung heart liva via center add organ
center penetr lung revenu forecast level surpass
anticip steadi growth center count continu end year
mid howev expect compani focus organ grow
exist activ center penetr deeper increas case per center versu
ad addit center heart expect y/i contribut
corpor growth numer catalyst heart could support
beyond growth includ fda heart panel panel follow approv
ii dcd program launch first implant done earlier month note
center count step materi track end
expect count reach liver like go flattish
howev upcom opportun drive growth back half
upsid includ liver pma approv oc liver protect data releas
logist challeng may cloud near-term trajectori discuss logist
challeng oc adopt particularli us lung us heart led
conserv estim note compani proactiv invest
address logist issu includ grow clinic support staff
improv coordin center although may earli see posit impact
earli nonetheless manag reiter confid
invest especi lung
improv gross margin coupl revenu outgrow opex expect gm take
anoth step toward long-term target end sg
like see given continu invest grow manpow resourc
smooth logist could rise primarili attribut compani
robust trail spend see exhibit catalyst tabl manag
express confid profit reach quarterli revenu
gm model impli larger revenu base may need profit break-even
given slower ramp project margin compar manag commentari
ebitda break-even achiev tandem
oc disrupt remain equal-weight visibl transmed oc pois
disrupt organ transplant space seen limit innov
standard care transport preserv donat organ remain
rudimentari cold storag thesi rest risk-adjust penetr
sizeabl ii seri potenti construct clinic data regulatori
catalyst remain pt impli ev sale repres
discount high growth smid cap peer set line lower end set
catalyst like drive debat
eu approv liver bile salt oc liver solut
oc respons fda defienc letter oc heart
heart standard expand pma approv
heart fda panel standard/expand
posit risk reward drive catalyst pathway potenti expans
posit risk reward drive catalyst pathway potenti expans
price target reflect multipl
base case sale high growth smid cap devic peer
support dcf wacc ww penetr
oc lung/heart assum sale grow compound-annual-growth-rate
driven differenti clinic econom valu proposit
oc momentum inflect faster sale revis higher multipl
expand oc lung heart adopt acceler fda approv
data inspir heart expand prove compel tam
expans increas lsd-msd msd-hsd penetr increas
pt us lung us heart oc us liver adopt
acceler doubl investor give credit liver given tam
ev/sal support dcf
ev/sal support dcf
oc potenti redefin organ transplant potenti improv
outcom cost econom suppli expans drive util oc lung
adopt standard criteria lung drive growth adopt expand
criteria lung drive adopt oc heart adopt standard
expand criteria heart drive adopt ev/sal multipl
peer group justifi peer growth prospect
switch commerci take longer expect upcom clinic data
point less compel limit regulatori approv adopt oc
drive increas volum penetr decreas pt
us lung us heart us liver adopt delay
clinic trial fall valuat multipl contract still recogn
growth potenti multibillion dollar
transmed oc paradigm chang
technolog allow market expans
sub-optimal organ donor pool extend
organ viabl transplant time pre-
screen organ function decreas
us heart/lung market
intermedi term oc grow transplant
volum lsd-msd annual
revenu growth driven oc
lung/heart limit contribut
data trial demonstr improv
outcom better cost econom vs
standard care drive increas physician
everi bp ww oc heart lung
combin penetr estim
gross margin increas
exhibit
risk achiev price
channel develop occur faster
slower pace physician adopt
less limit lead greater lower oc
fda heart panel posit potenti
reimburs prove less
rate limit util expect
data key trial demonstr
meaning better wors outcom
equal-weight price target recent strateg partnership
remov key overhang share cash need address howev came
expens materi dilut continu see long-term valu mr-linac
radiat oncolog see system superior key competitor
elekta howev path profit remain challeng like requir
addit financ within next sever year therefor balanc risk-
current valuat perform review
valuat current trade sale in-lin modestli
radiat oncolog peer elekta varian valuat becom greatli depress
start juli cut top-line guidanc rais cash burn guidanc
creat signific overhang share howev modestli reliev earli
decemb compani announc sever strateg partnership alongsid
equiti rais see valu dcf-basi price target
impli sale sale
announc collabor elekta advanc knowledg use mr-
guid radiat therapi clinic collabor explor
clinic benefit mridian see alongsid compani plan rais
proce howev ultim upsiz take dilut
prior announc estim cash would provid
runway addit like bring cash runway base
updat model although still profit although unconfirm
compani note taken posit investor share ralli
follow day signific dilut unexpect
lower revenu estim updat model reflect addit
cash modestli lower placement revenu assumpt
see given backlog convers outlook appear temper
order place revenu recognit take conserv approach
model unit placement vs estimate reflect revenu
y/i growth rel line consensu compani
take step increas time order instal ultim revenu
recognit could see upsid consensu number understand
shrink time order instal key prioriti manag
path profit remain challeng updat spend assumpt
next sever year incorpor slightli greater spend ramp
compani focus continu scale busi put profit
backburn model growth opex translat cash
burn remain view path profit remain steep
long may requir addit form financ base current model
profit reach cash turn neg
forecast addit potenti equiti rais
catalyst like drive debat
updat competit landscap on-going
mr linac superior innov
field radiat oncolog
abl penetr portion exist
view mridian
competit advantag elekta
base real-tim imag capabl
size system lower price point
profit remain headwind
price target base dcf-valuat
assum wacc termin growth rate impli
base case sale rel line modestli
radiat oncolog peer model system placement
plateau per year termin year oper margin
peak
mr-linac gain broad base traction academ center begin
penetr tradit hospit center abl captur maintain
market share vs elekta compani leverag instal base
drive recur stream servic revenu oper margin gradual expand
termin year
mr linac abl gradual gain traction lead academ center
commun hospit sustain two third market share
model termin year revenu growth msd/hsd system placement
peak per year oper profit break-even priorit nad
therefor achiev
mr linac broadli struggl gain adopt hospit given premium price
point suffici capabl tradit linear acceler burn
remain overhang busi rais sever addit
round dilut financ achiev profit within year
forese futur abl
gener suffici instal base drive
market penetr mr linac within
share breakdown
mridian elekta
pt organ growth
increment oper margin
expans termin year translat
increas dcf valuat
updat competit landscap
risk achiev price
mr linac struggl gain traction
hospit facil broadli given premium
increas invest inabl
overweight zimmer biomet price target vs prior share
outperform point compani proven abil
acceler top-line thesi advanc earlier anticip compani
reiter expect cc growth debat
center whether zimmer biomet acceler profil toward higher end
 leverag potenti activ
current valuat perform review
valuat zimmer biomet current trade ep
ebitda estim respect discount larg cap peer given lower organ
growth ep profil although narrow throughout compani
demonstr abil acceler growth ahead consensu estim valu
zimmer biomet ep turn discount peer given outsiz exposur
slow growth recon end market challeng balanc sheet
top-line acceler continu announc zimmer biomet
would reach wamgr growth month earlier anticip driven
point ytd rel out-performance zimmer biomet combin recent
manag commentari leav us view cc growth guidanc
like assum compani achiev growth impli
point momentum acceler see rosa placement contribut
revenu bp growth underli basi ex rosa impli
core cc growth vs estim core growth model cc
organ growth consensu cc includ addit
sell day discuss
bottom-up build see high end cc possibl despit challeng
comp knee brought broader market strength see
broader busi improv confid momentum build throughout
year busi fundament continu improv cementless mix improv
alongsid persona partial launch rosa placement drive implant pull-through
mention rosa placement drive bp ww knee growth
impli underli organ growth vs underli estim net
model ww knee organ growth drive bp corpor see hip
perform rel consist throughout year like grow line
market model organ set momentum acceler y/i driven sale
forc expans new product launch model organ bp
corpor recent invest dental driven faster segment recoveri
manag expect continu model growth stabil y/i impli
bp momentum acceler y/i spine weak like persist throughout
segment remain challeng rosa spine launch stabil growth
model segment growth net model organ growth note cc
growth aid one addit sell day drive bp tailwind full-
year cc growth see risk-adjust expect upsid throughout
ep growth profil becom key debat manag vocal regard
anticip gross margin headwind includ price higher cost
inventori flow cog model impli bp y/i declin gross margin
ep bp headwind convers growth acceler see sg
leverag like lead modest margin expans consist
manag commentari model bp y/i margin expans non-oper
leverag key compon ep growth forecast interest declin
y/i bp ep modest improv tax bp ep
view manag like guid ep growth bracket street
comfort modestli consensu y/i growth
see upsid factor top-line growth and/or non-oper leverag
note contribut point faster growth would drive bp ep
 activ like picks-up zimmer biomet paid debt
current net leverag commentari suggest
willing take leverag impli capac deal
despit see larger scale deal less like given busi
recent go offens begin execut larger scale acquisit may
ensu disrupt continu recoveri howev could scenario
compani referenc shift wamgr higher would like requir
deal outsid musculoskelet said tuck-in in-licens partnership within
adjac musculoskelet like occur capac
discuss zimmer biomet like interest bidder potenti divestitur
stryker/wmgi ankl portfolio see note knowledg
dd ep growth possibl model anoth year growth
acceler organ dynam leav true ep growth profil
unknown price continu bp drag gross margin higher
cost inventori anniversari creat less sever headwind
modest gm expans possibl earli tell like prove
swing factor msd/hsd ldd ep growth bp increment gm
drive bp ep growth expect sg leverag continu top-line
acceler model bp margin expans includ bp gm
expans absenc meaning interest continu tailwind
via paydown favor rate environ model y/i declin
drive bp ep consensu current model ep growth
see conserv model impli ep growth
see upsid number driven top-line acceler remain overweight
overweight thesi play earlier anticip reach market
growth achiev month earli could repres two consecut
year top bottom line acceler dynam remain key risk
current valuat price-to-earnings see market price
abil drive leverag remain underappreci posit view
predic top-line acceler broader busi momentum drive upsid
number leverag drive msd higher ep growth rais price
target vs prior base ep turn discount larg cap
catalyst like drive debat
potenti shift wamgr on-going
deriv base case scenario valu zimmer biomet
ep turn discount larg cap peer given outsiz
exposur slow growth recon end market challeng
zimmer biomet reach mid-singl digit growth driven rosa new product
launch broader busi recoveri activ augment
compani wamgr mid-singl digit compani abl gener
leverag via top-line growth margin expans drive consist dd ep
top-line growth acceler rosa placement drive growth
associ pull-through stabil share knee compani
demonstr modest margin improv alongsid non-oper
growth remain near lower end cc busi recoveri slow
rosa new product launch disappoint headwind price
higher cost inventori lead mute ep growth low-singl digit capit
deploy ineffici alloc lead busi disrupt
zimmer biomet demonstr
abil acceler top-line growth
cc expect continu driven
broader busi recoveri rosa
compani abl drive
modest leverag begin via
top-line growth drop-through slight
margin improv drop-through
balanc reinvest
potenti activ
shift wamgr higher lead
point top-line upsid drive bp
rosa placement drive bp
modest acceler knees/set
revenu drive point growth
buy-back drive bp ep
potenti shift wamgr on-going
risk achiev price
price pressur may acceler
pressur growth gross margin
higher cost inventori flow
driven mako
warn letter lead action
fda impact sale cost
exhibit rate price target chang coverag
valuat methodolog risk associ price target referenc research report pleas contact client support follow us/canada hong kong latin america
 london singapor sydney tokyo altern may contact invest repres morgan stanley research
return rel current stock price
perform valuat overview
anoth year medic devic strength despit healthcar under-perform
healthcar under-perform pt ytd vs
outperform vs medic devic
meaning outperform sector broader market ytd
pt ahead healthcar pt ahead said flow space
larg revers sinc end august see exhibit exhibit
coverag reach peak valuat premium widest spread
year multi-year move devic fuel improv fundament
structur drug suppli chain concern show sign strain investor
inch back reimburs regulatory-sensit sub-sector recogn elect
risk appear reflect idiosyncrat biotech catalyst
driven signific appreci last month sinc septemb devic
under-perform healthcar point respect see
finish like predictor start
exhibit roll week perform healthcar equip suppli vs
exhibit ytd perform med-tech subsector
exhibit ytd perform med-tech market cap
exhibit stock price perform vs ytd
outperform
outperform
under-perform
under-perform
note axi valu repres perform respect year
under-perform
outperform
sever compani histor pre-announc result and/or guidanc
earlier part year follow exhibit show histor pre-announc
last year
exhibit potenti ep impact devic tax
potenti ep impact devic tax
note exclud non-profit compani ep analysi
exhibit estim devic tax sale
estim devic tax sale
